

1. Vitols E, Linnane AW. Studies on the oxidative metabolism of *Saccharomyces cerevisiae*. II. Morphology and oxidative phosphorylation capacity of mitochondria and derived particles from baker's yeast. *The Journal of Biophysical and Biochemical Cytology*. 1961;9:701–710. [PMC free article] [PubMed]
2. Bellamy D. The endogenous citric acid-cycle intermediates and amino acids of. *The Biochemical Journal*. 1962;82:218–224. [PMC free article] [PubMed]
3. Richter C, Kass GEN. Oxidative stress in mitochondria: its relationship to cellular Ca²⁺ homeostasis, cell death, proliferation and differentiation. *Chemico-Biological Interactions*. 1991;77(1):1–23. [PubMed]
4. Sohal RS, Brunk UT. Mitochondrial production of pro-oxidants and cellular senescence. *Mutation Research—DNAging Genetic Instability and Aging*. 1992;275(3–6):295–304. [PubMed]
5. Piccolo G, Banfi P, Azan G, et al. Biological markers of oxidative stress in mitochondrial myopathies with progressive external ophthalmoplegia. *The Journal of the Neurological Sciences*. 1991;105(1):57–60. [PubMed]
6. Di Monte DA, Chan P, Sandy MS. Glutathione in Parkinson's disease: a link between oxidative stress and mitochondrial damage? *Annals of Neurology*. 1992;32(supplement):S111–S115. [PubMed]
7. Chinnery PF. Mitochondrial disorders overview. Synonyms: mitochondrial encephalomyopathies, mitochondrial myopathies, oxidative phosphorylation disorders, respiratory chain disorders. In: Pagon RA, Bird TD, Dolan CR, et al., editors. *GeneReviews*. Seattle, Wash, USA: University of Washington; 2010. pp. 1993–2013. <http://www.ncbi.nlm.nih.gov/books/NBK1116/>
8. Schon EA, di Mauro S, Hirano M. Human mitochondrial DNA: roles of inherited and somatic mutations. *Nature Reviews Genetics*. 2012;13(12):878–890. [PMC free article] [PubMed]
9. Carelli V, La Morgia C, Valentino ML, et al. Idebenone treatment in Leber's hereditary optic neuropathy. *Brain*. 2011;134(part 9):p. e188. [PubMed]
10. Kumar M, Kaur P, Kumar M, et al. Clinical characterization and mitochondrial DNA sequence variations in Leber hereditary optic neuropathy. *Molecular Vision*. 2012;18:2687–2699. [PMC free article] [PubMed]
11. Sadun AA, Chicani CF, Ross-Cisneros FN, et al. Effect of EPI-743 on the clinical course of the mitochondrial disease leber hereditary optic neuropathy. *Archives of Neurology*. 2012;69(3):331–338. [PubMed]
12. Martinelli D, Catteruccia M, Piemonte F, et al. EPI-743 reverses the progression of the pediatric mitochondrial disease—genetically defined Leigh Syndrome. *Molecular Genetics and Metabolism*. 2012;107(3):383–388. [PubMed]
13. Lebiecinska M, Karkucinska-Wieckowska A, Wojtala A, et al. Disrupted ATP synthase activity and mitochondrial hyperpolarisation-dependent oxidative stress is associated with p66Shc phosphorylation in fibroblasts of NARP patients. *International Journal of Biochemistry and Cell Biology*. 2013;45(1):141–150. [PubMed]
14. Mattiazzi M, Vijayvergiya C, Gajewski CD, et al. The mtDNA T8993G (NARP) mutation results in an impairment of oxidative phosphorylation that can be improved by antioxidants. *Human Molecular Genetics*. 2004;13(8):869–879. [PubMed]
15. Ihara Y, Kibata M, Hayabara T, et al. Free radicals in the cerebrospinal fluid are associated with neurological disorders including mitochondrial encephalomyopathy. *Biochemistry and Molecular Biology International*. 1997;42(5):937–947. [PubMed]
16. Vattemi G, Mechref Y, Marini M, et al. Increased protein nitration in mitochondrial diseases: evidence for vessel wall involvement. *Molecular and Cellular Proteomics*. 2011;10(4):M110.002964 [PMC free article] [PubMed]
17. Tan TMM, Caputo C, Medici F, et al. MELAS syndrome, diabetes and thyroid disease: the role of mitochondrial oxidative stress. *Clinical Endocrinology*. 2009;70(2):340–341. [PubMed]
18. Cotán D, Cordero MD, Garrido-Maraver J, et al. Secondary coenzyme Q(10) deficiency triggers

- mitochondria degradation by mitophagy in MELAS fibroblasts. *The FASEB Journal*. 2011;25(8):2669–2687. [PubMed]
19. Katayama Y, Maeda K, Iizuka T, et al. Accumulation of oxidative stress around the stroke-like lesions of MELAS patients. *Mitochondrion*. 2009;9(5):306–313. [PubMed]
20. Ma Y, Chen Y, Lu C, Liu C, Wei Y. Upregulation of matrix metalloproteinase 1 and disruption of mitochondrial network in skin fibroblasts of patients with MERRF syndrome. *Annals of the New York Academy of Sciences*. 2005;1042:55–63. [PubMed]
21. Wu S, Ma Y, Wu Y, Chen Y, Wei Y. Mitochondrial DNA mutation-elicited oxidative stress, oxidative damage, and altered gene expression in cultured cells of patients with MERRF syndrome. *Molecular Neurobiology*. 2010;41(2-3):256–266. [PubMed]
22. Salles JE, Moisés VA, Almeida DR, Chacra AR, Moisés RS. Myocardial dysfunction in mitochondrial diabetes treated with Coenzyme Q10. *Diabetes Research and Clinical Practice*. 2006;72(1):100–103. [PubMed]
23. Lax NZ, Campbell GR, Reeve AK, et al. Loss of myelin-associated glycoprotein in Kearns-Sayre syndrome. *Archives of Neurology*. 2012;69(4):490–499. [PMC free article] [PubMed]
24. Mancuso M, Orsucci D, Calsolaro V, et al. Tetracycline treatment in patients with progressive external ophthalmoplegia. *Acta Neurologica Scandinavica*. 2011;124(6):417–423. [PubMed]
25. Wolf J, Obermaier-Kusser B, Jacobs M, et al. A new mitochondrial point mutation in the transfer RNA^{Lys} gene associated with progressive external ophthalmoplegia with impaired respiratory regulation. *The Journal of the Neurological Sciences*. 2012;316(1-2):108–111. [PubMed]
26. Manea EM, Leverger G, Bellmann F, et al. Pearson syndrome in the neonatal period: two case reports and review of the literature. *Journal of Pediatric Hematology/Oncology*. 2009;31(12):947–951. [PubMed]
27. Kefala-Agoropoulou K, Roilides E, Lazaridou A, et al. Pearson syndrome in an infant heterozygous for C282Y allele of HFE gene. *Hematology*. 2007;12(6):549–553. [PubMed]
28. Uusimaa J, Finnilä S, Vainionpää L, et al. A mutation in mitochondrial DNA-encoded cytochrome c oxidase II gene in a child with Alpers-Huttenlocher-like disease. *Pediatrics*. 2003;111(3):e262–e268. [PubMed]
29. de Vries MC, Rodenburg RJ, Morava E, et al. Multiple oxidative phosphorylation deficiencies in severe childhood multi-system disorders due to polymerase gamma (POLG1) mutations. *European Journal of Pediatrics*. 2007;166(3):229–234. [PubMed]
30. Lewis W, Day BJ, Kohler JJ, et al. Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase γ Laboratory Investigation. 2007;87(4):326–335. [PMC free article] [PubMed]
31. Saneto RP, Cohen BH, Copeland WC, et al. Alpers-Huttenlocher Syndrome. *Pediatric Neurology*. 2013;48(3):167–178. [PMC free article] [PubMed]
32. Hirano M, Garone C, Quinzii CM. CoQ10 deficiencies and MNGIE: two treatable mitochondrial disorders. *Biochimica et Biophysica Acta—General Subjects*. 2012;1820(5):625–631. [PMC free article] [PubMed]
33. El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. *Neurotherapeutics*. 2013;10(2):186–198. [PMC free article] [PubMed]
34. DiMauro S, Schon EA, Carelli V, et al. The clinical maze of mitochondrial neurology. *Nature Reviews Neurology*. 2013;9:429–444. [PMC free article] [PubMed]
35. Barzilai A, Rotman G, Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. *DNA Repair*. 2002;1(1):3–25. [PubMed]
36. Ambrose M, Goldstine JV, Gatti RA. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. *Human Molecular Genetics*. 2007;16(18):2154–2164. [PubMed]
37. Degan P, d'Ischia M, Pallardó FV, et al. Glutathione levels in blood from ataxia telangiectasia

- patients suggest in vivo adaptive mechanisms to oxidative stress. *Clinical Biochemistry*. 2007;40(9-10):666–670. [PubMed]
38. Valentin-Vega YA, MacLean KH, Tait-Mulder J, et al. Mitochondrial dysfunction in ataxia-telangiectasia. *Blood*. 2012;119(6):1490–1500. [PMC free article] [PubMed]
 39. Shiloh Y, Tabor E, Becker Y. Abnormal response of ataxia-telangiectasia cells to agents that break the deoxyribose moiety of DNA via a targeted free radical mechanism. *Carcinogenesis*. 1983;4(10):1317–1322. [PubMed]
 40. Poot M, Hoehn H, Nicotera TM, Rudiger HW. Cell kinetic evidence suggests elevated oxidative stress in cultured cells of Bloom's syndrome. *Free Radical Research Communications*. 1989;7(3–6):179–187. [PubMed]
 41. Nicotera TM. Molecular and biochemical aspects of Bloom's syndrome. *Cancer Genetics and Cytogenetics*. 1991;53(1):1–13. [PubMed]
 42. Zatterale A, Kelly FJ, Degan P, et al. Oxidative stress biomarkers in four Bloom syndrome (BS) patients and in their parents suggest in vivo redox abnormalities in BS phenotype. *Clinical Biochemistry*. 2007;40(15):1100–1110. [PubMed]
 43. Javeri A, Guy Lyons J, Huang XX, Halliday GM. Downregulation of Cockayne syndrome B protein reduces human 8-oxoguanine DNA glycosylase-1 expression and repair of UV radiation-induced 8-oxo-7,8-dihydro-2'-deoxyguanine. *Cancer Science*. 2011;102(9):1651–1658. [PubMed]
 44. Pascucci B, Lemma T, Iorio E, et al. An altered redox balance mediates the hypersensitivity of Cockayne syndrome primary fibroblasts to oxidative stress. *Aging Cell*. 2012;11(3):520–529. [PubMed]
 45. Scheibye-Knudsen M, Ramamoorthy M, Sykora P, et al. Cockayne syndrome group B protein prevents the accumulation of damaged mitochondria by promoting mitochondrial autophagy. *The Journal of Experimental Medicine*. 2012;209(4):855–869. [PMC free article] [PubMed]
 46. Kamenisch Y, Berneburg M. Mitochondrial CSA and CSB: protein interactions and protection from ageing associated DNA mutations. *Mechanisms of Ageing and Development*. 2013;134(5-6):270–274. [PubMed]
 47. Pallardó FV, Degan P, d'Ischia M, et al. Higher age-related prooxidant state in young Down syndrome patients indicates accelerated aging. *Biogerontology*. 2006;7(4):211–220. [PubMed]
 48. Tiano L, Padella L, Carnevali P, et al. Coenzyme Q(10) and oxidative imbalance in Down syndrome: biochemical and clinical aspects. *BioFactors*. 2008;32(1–4):161–167. [PubMed]
 49. Tiano L, Busciglio J. Mitochondrial dysfunction and Down's syndrome: is there a role for coenzyme Q(10)? *BioFactors*. 2011;37(5):386–392. [PubMed]
 50. Valenti D, Manente GA, Moro L, Marra E, Vacca RA. Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway. *Biochemical Journal*. 2011;435(3):679–688. [PubMed]
 51. Valenti D, de Rasmio D, Signorile A, et al. Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome. *Biochimica et Biophysica Acta*. 2013;1832(4):542–552. [PubMed]
 52. Bambrick LL, Fiskum G. Mitochondrial dysfunction in mouse trisomy 16 brain. *Brain Research*. 2008;1188(1):9–16. [PubMed]
 53. Brooksbank BW, Balazs R. Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain. *Brain Research*. 1984;318(1):37–44. [PubMed]
 54. Joenje H, Arwert F, Eriksson AW. Oxygen-dependence of chromosomal aberrations in Fanconi's anaemia. *Nature*. 1981;290(5802):142–143. [PubMed]
 55. Pagano G, Aiello Talamanca A, Castello G, et al. From clinical description to in vitro and animal studies, and backwards to patients: oxidative stress and mitochondrial dysfunction in Fanconi anemia. *Free Radical Biology and Medicine*. 2013;58:118–125. [PubMed]

56. Du W, Rani R, Sipple J, et al. The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. *Blood*. 2012;119(18):4142–4151. [PMC free article] [PubMed]
57. Mukhopadhyay SS, Leung KS, Hicks MJ, Hastings PJ, Youssoufian H, Plon SE. Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia. *The Journal of Cell Biology*. 2006;175(2):225–235. [PMC free article] [PubMed]
58. Kumari U, Jun WY, Bay BH, et al. Evidence of mitochondrial dysfunction and impaired ROS detoxifying machinery in Fanconi anemia cells. *Oncogene*. 2013;33(2):165–172. [PubMed]
59. Ravera S, Vaccaro D, Cuccarolo P, et al. Mitochondrial respiratory chain Complex I defects in Fanconi anemia complementation group A. *Biochimie*. 2013;95(10):1828–1837. [PubMed]
60. Pagano G, Aiello Talamanca A, Castello G, et al. Bone marrow cell transcripts from Fanconi anaemia patients reveal in vivo alterations in mitochondrial, redox and DNA repair pathways. *European Journal of Haematology*. 2013;91(2):141–151. [PubMed]
61. Viteri G, Chung YW, Stadtman ER. Effect of progerin on the accumulation of oxidized proteins in fibroblasts from Hutchinson Gilford progeria patients. *Mechanisms of Ageing and Development*. 2010;131(1):2–8. [PMC free article] [PubMed]
62. Richards SA, Muter J, Ritchie P, Lattanzi G, Hutchison CJ. The accumulation of un-repairable DNA damage in laminopathy progeria fibroblasts is caused by ROS generation and is prevented by treatment with N-acetyl cysteine. *Human Molecular Genetics*. 2011;20(20):3997–4004. [PubMed]
63. Turinetto V, Porcedda P, Minieri V, et al. A novel defect in mitochondrial p53 accumulation following DNA damage confers apoptosis resistance in Ataxia Telangiectasia and Nijmegen Breakage Syndrome T-cells. *DNA Repair*. 2010;9(11):1200–1208. [PubMed]
64. Krenzlin H, Demuth I, Salewsky B, et al. DNA damage in nijmegen breakage syndrome cells leads to PARP hyperactivation and increased oxidative stress. *PLoS Genetics*. 2012;8(3)e1002557 [PMC free article] [PubMed]
65. Woo LL, Futami K, Shimamoto A, Furuichi Y, Frank KM. The Rothmund-Thomson gene product RECQL4 localizes to the nucleolus in response to oxidative stress. *Experimental Cell Research*. 2006;312(17):3443–3457. [PubMed]
66. Davis T, Tivey HS, Brook AJ, et al. Activation of p38 MAP kinase and stress signalling in fibroblasts from the progeroid Rothmund-Thomson syndrome. *Age*. 2013;35(5):1767–1783. [PMC free article] [PubMed]
67. Croteau DL, Rossi ML, Canugovi C, et al. RECQL4 localizes to mitochondria and preserves mitochondrial DNA integrity. *Aging Cell*. 2012;11(3):456–466. [PMC free article] [PubMed]
68. Pallardó FV, Lloret A, Lebel M, et al. Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. *Biogerontology*. 2010;11(4):401–419. [PubMed]
69. Bohr VA, Cooper M, Orren D, et al. Werner syndrome protein: biochemical properties and functional interactions. *Experimental Gerontology*. 2000;35(6-7):695–702. [PubMed]
70. von Kobbe C, May A, Grandori C, Bohr VA. Werner syndrome cells escape hydrogen peroxide-induced cell proliferation arrest. *The FASEB Journal*. 2004;18(15):1970–1972. [PubMed]
71. Pagano G, Zatterale A, Degan P, et al. Multiple involvement of oxidative stress in Werner syndrome phenotype. *Biogerontology*. 2005;6(4):233–243. [PubMed]
72. Lloret A, Calzone R, Dunster C, et al. Different patterns of in vivo pro-oxidant states in a set of cancer- or aging-related genetic diseases. *Free Radical Biology and Medicine*. 2008;44(4):495–503. [PubMed]
73. Hayashi M. Roles of oxidative stress in xeroderma pigmentosum. *Advances in Experimental Medicine and Biology*. 2008;637:120–127. [PubMed]
74. Ting APL, Low GKM, Gopalakrishnan K, Hande MP. Telomere attrition and genomic instability in xeroderma pigmentosum type-b deficient fibroblasts under oxidative stress. *Journal of Cellular and*

- Molecular Medicine. 2010;14(1-2):403–416. [PMC free article] [PubMed]
75. Rezvani HR, Rossignol R, Ali N, et al. XPC silencing in normal human keratinocytes triggers metabolic alterations through NOX-1 activation-mediated reactive oxygen species. *Biochimica et Biophysica Acta—Bioenergetics*. 2011;1807(6):609–619. [PMC free article] [PubMed]
76. Tanaka J, Nagai T, Okada S. Serum concentration of coenzyme Q in xeroderma pigmentosum. *Clinical Neurology*. 1998;38(1):57–59. [PubMed]
77. Xia X, Werner D, Popanda O, Thielmann HW. Expression of mitochondrial genes and DNA-repair-related nuclear genes is altered in xeroderma pigmentosum fibroblasts. *The Journal of Cancer Research and Clinical Oncology*. 1994;120(8):454–464. [PubMed]
78. Deon M, Sitta A, Barschak AG, et al. Induction of lipid peroxidation and decrease of antioxidant defenses in symptomatic and asymptomatic patients with X-linked adrenoleukodystrophy. *International Journal of Developmental Neuroscience*. 2007;25(7):441–444. [PubMed]
79. Petrillo S, Piemonte F, Pastore A, et al. Glutathione imbalance in patients with X-linked adrenoleukodystrophy. *Molecular Genetics and Metabolism*. 2013;109(4):366–370. [PMC free article] [PubMed]
80. Schlüter A, Espinosa L, Fourcade S, et al. Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy. *Human Molecular Genetics*. 2012;21(5):1062–1077. [PMC free article] [PubMed]
81. López-Erauskin J, Galino J, Ruiz M, et al. Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. *Human Molecular Genetics*. 2013;22(16):3296–3305. [PubMed]
82. Fourcade S, López-Erauskin J, Ruiz M, et al. Mitochondrial dysfunction and oxidative damage cooperatively fuel axonal degeneration in X-linked adrenoleukodystrophy. *Biochimie*. 2014;98:143–149. [PubMed]
83. Terrill JR, Radley-Crabb HG, Iwasaki T, et al. Oxidative stress and pathology in muscular dystrophies: focus on protein thiol oxidation and dysferlinopathies. *FEBS Journal*. 2013;280(17):4149–4164. [PubMed]
84. Renjini R, Gayathri N, Nalini A, Srinivas Bharath MM. Oxidative damage in muscular dystrophy correlates with the severity of the pathology: role of glutathione metabolism. *Neurochemical Research*. 2012;37(4):885–898. [PubMed]
85. Percival JM, Siegel MP, Knowels G, et al. Defects in mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne muscular dystrophy are not alleviated by PDE5 inhibition. *Human Molecular Genetics*. 2013;22(1):153–167. [PMC free article] [PubMed]
86. Cooper JM, Korlipara LVP, Hart PE, Bradley JL, Schapira AHV. Coenzyme Q(10) and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin e and coenzyme Q(10) therapy. *The European Journal of Neurology*. 2008;15(12):1371–1379. [PubMed]
87. Sparaco M, Gaeta LM, Santorelli FM, et al. Friedreich's ataxia: oxidative stress and cytoskeletal abnormalities. *The Journal of the Neurological Sciences*. 2009;287(1-2):111–118. [PubMed]
88. Santos R, Lefevre S, Sliwa D, Seguin A, Camadro J, Lesuisse E. Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. *Antioxidants and Redox Signaling*. 2010;13(5):651–690. [PMC free article] [PubMed]
89. Hyson HC, Kiebertz K, Shoulson I, et al. Safety and tolerability of high-dosage coenzyme Q(10) in Huntington's disease and healthy subjects. *Movement Disorders*. 2010;25(12):1924–1928. [PubMed]
90. Valencia A, Sapp E, Kimm JS, et al. Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease. *Human Molecular Genetics*. 2013;22(6):1112–1131. [PMC free article] [PubMed]
91. Yang L, Calingasan NY, Wille EJ, et al. Combination therapy with Coenzyme Q(10) and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.

- Journal of Neurochemistry. 2009;109(5):1427–1439. [PMC free article] [PubMed]
92. Ribeiro M, Silva AC, Rodrigues J, et al. Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells—protective effect of cystamine and creatine. *Toxicological Sciences*. 2013;136(2):487–499. [PubMed]
93. Tyagi N, Ovechkin AV, Lominadze D, Moshal KS, Tyagi SC. Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. *Journal of Cellular Biochemistry*. 2006;98(5):1150–1162. [PMC free article] [PubMed]
94. Moshal KS, Tipparaju SM, Vacek TP, et al. Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. *The American Journal of Physiology—Heart and Circulatory Physiology*. 2008;295(2):H890–H897. [PMC free article] [PubMed]
95. Vanzin CS, Biancini GB, Sitta A, et al. Experimental evidence of oxidative stress in plasma of homocystinuric patients: a possible role for homocysteine. *Molecular Genetics and Metabolism*. 2011;104(1-2):112–117. [PubMed]
96. Nur E, Brandjes DP, Schnog JB, et al. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients. *British Journal of Haematology*. 2010;151(1):62–69. [PubMed]
97. Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. *British Journal of Haematology*. 2006;132(1):108–113. [PubMed]
98. Grasso JA, Sullivan AL, Sullivan LW. Ultrastructural studies of the bone marrow in sickle cell anaemia. I. The structure of sickled erythrocytes and reticulocytes and their phagocytic destruction. *British Journal of Haematology*. 1975;31(2):135–148. [PubMed]
99. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. *Annals of the New York Academy of Sciences*. 2010;1202:1–9. [PubMed]
100. Ferro E, Visalli G, Civa R, et al. Oxidative damage and genotoxicity biomarkers in transfused and untransfused thalassemic subjects. *Free Radical Biology and Medicine*. 2012;53(10):1829–1837. [PubMed]
101. Tsagris V, Liapi-Adamidou G. Serum carnitine levels in patients with homozygous beta thalassemia: a possible new role for carnitine? *European Journal of Pediatrics*. 2005;164(3):131–134. [PubMed]
102. Rebrin I, Sohal RS. Pro-oxidant shift in glutathione redox state during aging. *Advanced Drug Delivery Reviews*. 2008;60(13-14):1545–1552. [PMC free article] [PubMed]
103. Møller P, Løhr M, Folkmann JK, Mikkelsen L, Loft S. Aging and oxidatively damaged nuclear DNA in animal organs. *Free Radical Biology and Medicine*. 2010;48(10):1275–1285. [PubMed]
104. Cau SB, Carneiro FS, Tostes RC. Differential modulation of nitric oxide synthases in aging: therapeutic opportunities. *Frontiers in Physiology*. 2012;3(article 218) [PMC free article] [PubMed]
105. Musicco C, Capelli V, Pesce V, et al. Accumulation of overoxidized Peroxiredoxin III in aged rat liver mitochondria. *Biochimica et Biophysica Acta—Bioenergetics*. 2009;1787(7):890–896. [PubMed]
106. Wang CH, Wu SB, Wu YT, et al. Oxidative stress response elicited by mitochondrial dysfunction: implication in the pathophysiology of aging. *Experimental Biology and Medicine*. 2013;238(5):450–460. [PubMed]
107. Gomez-Cabrera MC, Sanchis-Gomar F, Garcia-Valles R, et al. Mitochondria as sources and targets of damage in cellular aging. *Clinical Chemistry and Laboratory Medicine*. 2012;50(8):1287–1295. [PubMed]
108. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. *Hypertension*. 2007;49(2):241–248. [PubMed]
109. Victor VM, Rocha M, Solá E, Bañuls C, Garcia-Malpartida K, Hernández-Mijares A. Oxidative stress, endothelial dysfunction and atherosclerosis. *Current Pharmaceutical Design*. 2009;15(26):2988–3002. [PubMed]
110. Di Lisa F, Kaludercic N, Carpi A, Menabò R, Giorgio M. Mitochondria and vascular pathology.

- Pharmacological Reports. 2009;61(1):123–130. [PubMed]
111. Perrotta I, Perrotta E, Sesti S, et al. MnSOD expression in human atherosclerotic plaques: an immunohistochemical and ultrastructural study. *Cardiovascular Pathology*. 2013;22(6):428–437. [PubMed]
 112. Sobenin IA, Sazonova MA, Postnov AY, et al. Changes of mitochondria in atherosclerosis: possible determinant in the pathogenesis of the disease. *Atherosclerosis*. 2013;227(2):283–288. [PubMed]
 113. Guzik B, Sagan A, Ludew D, et al. Mechanisms of oxidative stress in human aortic aneurysms—association with clinical risk factors for atherosclerosis and disease severity. *International Journal of Cardiology*. 2013;168(3):2389–2396. [PMC free article] [PubMed]
 114. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. *The Journal of Clinical Endocrinology and Metabolism*. 2004;89(10):4963–4971. [PubMed]
 115. Palmieri VO, Grattagliano I, Portincasa P, Palasciano G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. *The Journal of Nutrition*. 2006;136(12):3022–3026. [PubMed]
 116. Koene S, Rodenburg RJ, van der Knaap MS, et al. Natural disease course and genotype-phenotype correlations in Complex I deficiency caused by nuclear gene defects: what we learned from 130 cases. *Journal of Inherited Metabolic Diseases*. 2012;35(5):737–747. [PMC free article] [PubMed]
 117. Huang C, Su S, Hsieh M, et al. Depleted leukocyte mitochondrial DNA copy number in metabolic syndrome. *Journal of Atherosclerosis and Thrombosis*. 2011;18(10):867–873. [PubMed]
 118. Mitchell T, Darley-Usmar V. Metabolic syndrome and mitochondrial dysfunction: insights from preclinical studies with a mitochondrially targeted antioxidant. *Free Radical Biology and Medicine*. 2012;52(5):838–840. [PMC free article] [PubMed]
 119. Auinger A, Rubin D, Sabandal M, et al. A common haplotype of carnitine palmitoyltransferase 1b is associated with the metabolic syndrome. *British Journal of Nutrition*. 2013;109(5):810–815. [PubMed]
 120. Altindag O, Erel O, Aksoy N, Selek S, Celik H, Karaoglanoglu M. Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis. *Rheumatology International*. 2007;27(4):339–344. [PubMed]
 121. Fernandez-Moreno M, Soto-Hermida A, Pertega S, et al. Mitochondrial DNA (mtDNA) haplogroups and serum levels of anti-oxidant enzymes in patients with osteoarthritis. *BMC Musculoskeletal Disorders*. 2011;12, article 264 [PMC free article] [PubMed]
 122. Li Z, Shen J, Chen Y, et al. Mitochondrial genome sequencing of chondrocytes in osteoarthritis by human mitochondria RT2 Profiler PCR array. *Molecular Medicine Reports*. 2012;6(1):39–44. [PubMed]
 123. Fernández-Moreno M, Soto-Hermida A, Oreiro N, et al. Mitochondrial haplogroups define two phenotypes of osteoarthritis. *Frontiers in Physiology*. 2012;3(article 129) [PMC free article] [PubMed]
 124. Gavrilidis C, Miwa S, von Zglinicki T, et al. Mitochondrial dysfunction in osteoarthritis is associated with down-regulation of superoxide dismutase 2. *Arthritis and Rheumatism*. 2013;65(5):378–387. [PubMed]
 125. Tabak O, Gelisgen R, Erman H, et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. *Clinical and Investigative Medicine*. 2011;34(3):E163–E171. [PubMed]
 126. Remor AP, de Matos FJ, Ghisoni K, et al. Differential effects of insulin on peripheral diabetes-related changes in mitochondrial bioenergetics: involvement of advanced glycosylated end products. *Biochimica et Biophysica Acta—Molecular Basis of Disease*. 2011;1812(11):1460–1471. [PubMed]
 127. Bansal S, Siddarth M, Chawla D, Banerjee BD, Madhu SV, Tripathi AK. Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro.

- Molecular and Cellular Biochemistry. 2012;361(1-2):289–296. [PubMed]
128. Noriega-Cisneros R, Cortés-Rojo C, Manzo-Avalos S, et al. Mitochondrial response to oxidative and nitrosative stress in early stages of diabetes. *Mitochondrion*. 2013;13(6):835–840. [PubMed]
129. Amer MA, Ghattas MH, Abo-Elmatty DM, et al. Influence of glutathione S-transferase polymorphisms on type-2 diabetes mellitus risk. *Genetics and Molecular Research*. 2011;10(4):3722–3730. [PubMed]
130. Khan S, Raghuram GV, Bhargava A, et al. Role and clinical significance of lymphocyte mitochondrial dysfunction in type 2 diabetes mellitus. *Translational Research*. 2011;158(6):344–359. [PubMed]
131. Avila C, Huang RJ, Stevens MV, et al. Platelet mitochondrial dysfunction is evident in type 2 diabetes in association with modifications of mitochondrial anti-oxidant stress proteins. *Experimental and Clinical Endocrinology and Diabetes*. 2012;120(4):248–251. [PubMed]
132. Calabrese V, Cornelius C, Leso V, et al. Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes. *Biochimica et Biophysica Acta—Molecular Basis of Disease*. 2012;1822(5):729–736. [PubMed]
133. Gray SP, Di Marco E, Okabe J, et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. *Circulation*. 2013;127(18):1888–1902. [PubMed]
134. Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. *The EMBO Journal*. 2012;31(21):4106–4123. [PMC free article] [PubMed]
135. Atamna H, Frey WH, II Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. *Mitochondrion*. 2007;7(5):297–310. [PubMed]
136. Dumont M, Kipiani K, Yu F, et al. Coenzyme Q(10) decreases amyloid pathology and improves behavior in a transgenic mouse model of alzheimer's disease. *The Journal of Alzheimer's Disease*. 2011;27(1):211–223. [PMC free article] [PubMed]
137. Murakami K, Murata N, Noda Y, et al. Stimulation of the amyloidogenic pathway by cytoplasmic superoxide radicals in an Alzheimer's disease mouse model. *Bioscience, Biotechnology, and Biochemistry*. 2012;76(6):1098–1103. [PubMed]
138. Hardas SS, Sultana R, Clark AM, et al. Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. *Redox Biology*. 2013;1(1):80–85. [PMC free article] [PubMed]
139. Aliev G, Palacios HH, Gasimov E, et al. Oxidative stress induced mitochondrial failure and vascular hypoperfusion as a key initiator for the development of alzheimer disease. *Pharmaceuticals*. 2010;3(1):158–187.
140. Zarrouk A, Vejux A, Nury T, et al. Induction of mitochondrial changes associated with oxidative stress on very long chain fatty acids (C22:0, C24:0, or C26:0)-treated human neuronal cells (SK-NB-E) *Oxidative Medicine and Cellular Longevity*. 2012;2012:15 pages.623257 [PMC free article] [PubMed]
141. Kou J, Kovacs GG, Höftberger R, et al. Peroxisomal alterations in Alzheimer's disease. *Acta Neuropathologica*. 2011;122(3):271–283. [PMC free article] [PubMed]
142. Cozzolino M, Carri MT. Mitochondrial dysfunction in ALS. *Progress in Neurobiology*. 2012;97(2):54–66. [PubMed]
143. Cova E, Bongioanni P, Cereda C, et al. Time course of oxidant markers and antioxidant defenses in subgroups of amyotrophic lateral sclerosis patients. *Neurochemistry International*. 2010;56(5):687–693. [PubMed]
144. Karch CM, Prudencio M, Winkler DD, Hart PJ, Borchelt DR. Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(19):7774–7779. [PMC free article] [PubMed]
145. Rodríguez GE, González DM, Monachelli GM, et al. Morphological abnormalities in mitochondria of the skin of patients with sporadic amyotrophic lateral sclerosis. *Arquivos de Neuro-Psiquiatria*. 2012;70(1):40–44. [PubMed]

146. Ghiasi P, Hosseinkhani S, Noori A, Nafissi S, Khajeh K. Mitochondrial complex I deficiency and ATP/ADP ratio in lymphocytes of amyotrophic lateral sclerosis patients. *Neurological Research*. 2012;34(3):297–303. [PubMed]
147. Chuang Y. Mitochondrial dysfunction and oxidative stress in seizure-induced neuronal cell death. *Acta Neurologica Taiwanica*. 2010;19(1):3–15. [PubMed]
148. Malinska D, Kulawiak B, Kudin AP, et al. Complex III-dependent superoxide production of brain mitochondria contributes to seizure-related ROS formation. *Biochimica et Biophysica Acta—Bioenergetics*. 2010;1797(6-7):1163–1170. [PubMed]
149. Mayr JA, Zimmermann FA, Fauth C, et al. Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. *American Journal of Human Genetics*. 2011;89(6):792–797. [PMC free article] [PubMed]
150. García-Giménez JL, Seco-Cervera M, Aguado C, et al. Lafora disease fibroblasts exemplify the molecular interdependence between thioredoxin 1 and the proteasome in mammalian cells. *Free Radical Biology and Medicine*. 2013;65:347–359. [PubMed]
151. Booth NE, Myhill S, McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) *International Journal of Clinical and Experimental Medicine*. 2012;5(3):208–220. [PMC free article] [PubMed]
152. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. *Neuroendocrinology Letters*. 2009;30(6):715–722. [PubMed]
153. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Coenzyme Q(10) deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. *Neuroendocrinology Letters*. 2009;30(4):470–476. [PubMed]
154. Maes M, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased plasma peroxides as a marker of oxidative stress in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) *Medical Science Monitor*. 2011;17(4):SC11–SC15. [PMC free article] [PubMed]
155. Jammes Y, Steinberg JG, Delliaux S. Chronic fatigue syndrome: acute infection and history of physical activity affect resting levels and response to exercise of plasma oxidant/antioxidant status and heat shock proteins. *Journal of Internal Medicine*. 2012;272(1):74–84. [PubMed]
156. Smits B, van den Heuvel L, Knoop H, et al. Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome. *Mitochondrion*. 2011;11(5):735–738. [PubMed]
157. Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. *Clinical Biochemistry*. 2012;45(1-2):26–30. [PubMed]
158. Fischer MT, Sharma R, Lim JL, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. *Brain*. 2012;135(part 3):886–899. [PMC free article] [PubMed]
159. Campbell GR, Mahad DJ. Clonal expansion of mitochondrial DNA deletions and the progression of multiple sclerosis. *CNS and Neurological Disorders—Drug Targets*. 2012;11(5):589–597. [PubMed]
160. Miller E, Walczak A, Majsterek I, et al. Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course. *Journal of Neuroimmunology*. 2013;257(1-2):97–101. [PubMed]
161. Seet RCS, Lee CJ, Lim ECH, et al. Oxidative damage in Parkinson disease: measurement using accurate biomarkers. *Free Radical Biology and Medicine*. 2010;48(4):560–566. [PubMed]
162. Mischley LK, Allen J, Bradley R. Coenzyme Q(10) deficiency in patients with Parkinson's disease. *The*

- Journal of the Neurological Sciences. 2012;318(1-2):72–75. [PMC free article] [PubMed]
163. Naoi M, Maruyama W, Shamoto-Nagai M, Yi H, Akao Y, Tanaka M. Oxidative stress in mitochondria: decision to survival and death of neurons in neurodegenerative disorders. *Molecular Neurobiology*. 2005;31(1–3):81–93. [PubMed]
164. Danielson SR, Held JM, Oo M, Riley R, Gibson BW, Andersen JK. Quantitative mapping of reversible mitochondrial complex I cysteine oxidation in a Parkinson disease mouse model. *The Journal of Biological Chemistry*. 2011;286(9):7601–7608. [PMC free article] [PubMed]
165. Cacciatore I, Baldassarre L, Fornasari E, et al. Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems. *Oxidative Medicine and Cellular Longevity*. 2012;2012:12 pages.240146 [PMC free article] [PubMed]
166. Rose S, Melnyk S, Trusty TA, et al. Intracellular and extracellular redox status and free radical generation in primary immune cells from children with autism. *Autism Research and Treatment*. 2012;2012:10 pages.986519 [PMC free article] [PubMed]
167. Pecorelli A, Leoncini S, de Felice C, et al. Non-protein-bound iron and 4-hydroxynonenal protein adducts in classic autism. *Brain and Development*. 2013;35(2):146–154. [PubMed]
168. Frustaci A, Neri M, Cesario A, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. *Free Radical Biology and Medicine*. 2012;52(10):2128–2141. [PubMed]
169. Rose S, Melnyk S, Pavliv O, et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. *Translational Psychiatry*. 2012;2(article e134) [PMC free article] [PubMed]
170. Anitha A, Nakamura K, Thanseem I, et al. Downregulation of the expression of mitochondrial electron transport complex genes in autism brains. *Brain Pathology*. 2013;23(3):294–302. [PubMed]
171. Napoli E, Wong S, Giulivi C. Evidence of reactive oxygen species-mediated damage to mitochondrial DNA in children with typical autism. *Molecular Autism*. 2013;4(1):p. 2. [PMC free article] [PubMed]
172. Ross-Inta C, Omanska-Klusek A, Wong S, et al. Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. *Biochemical Journal*. 2010;429(3):545–552. [PMC free article] [PubMed]
173. Banerjee U, Dasgupta A, Rout JK, Singh OP. Effects of lithium therapy on Na⁺-K⁺-ATPase activity and lipid peroxidation in bipolar disorder. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2012;37(1):56–61. [PubMed]
174. Raffa M, Barhoumi S, Atig F, et al. Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2012;39(2):371–375. [PubMed]
175. Andreazza AC, Wang JF, Salmasi F, et al. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. *Journal of Neurochemistry*. 2013;127(4):552–561. [PubMed]
176. Rawdin BS, Mellon SH, Dhabhar FS, et al. Dysregulated relationship of inflammation and oxidative stress in major depression. *Brain, Behavior, and Immunity*. 2013;31(1):143–152. [PMC free article] [PubMed]
177. Szuster-Ciesielska A, Słotwińska M, Stachura A, et al. Accelerated apoptosis of blood leukocytes and oxidative stress in blood of patients with major depression. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2008;32(3):686–694. [PubMed]
178. Gibson SA, Korade Ž, Shelton RC. Oxidative stress and glutathione response in tissue cultures from persons with major depression. *Journal of Psychiatric Research*. 2012;46(10):1326–1632. [PMC free article] [PubMed]
179. Ben-Shachar D, Karry R. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. *PLoS ONE*. 2008;3(11)e3676 [PMC free article] [PubMed]
180. Chakraborty S, Singh OP, Dasgupta A, Mandal N, Das HN. Correlation between lipid peroxidation-

- induced TBARS level and disease severity in obsessive-compulsive disorder. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2009;33(2):363–366. [PubMed]
181. Behl A, Swami G, Sircar SS, Bhatia MS, Banerjee BD. Relationship of possible stress-related biochemical markers to oxidative/antioxidative status in obsessive-compulsive disorder. *Neuropsychobiology*. 2010;61(4):210–214. [PubMed]
182. Orhan N, Kucukali CI, Cakir U, Seker N, Aydin M. Genetic variants in nuclear-encoded mitochondrial proteins are associated with oxidative stress in obsessive compulsive disorders. *Journal of Psychiatric Research*. 2012;46(2):212–218. [PubMed]
183. Anderson G, Maes M, Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2013;42:101–114. [PubMed]
184. Pedrini M, Massuda R, Fries GR, et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. *Journal of Psychiatric Research*. 2012;46(6):819–824. [PubMed]
185. Kulak A, Steullet P, Cabungcal JH, et al. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. *Antioxidants and Redox Signaling*. 2012;18(12):1428–1443. [PubMed]
186. Zhang XY, Chen DC, Xiu MH, et al. Plasma total antioxidant status and cognitive impairments in schizophrenia. *Schizophrenia Research*. 2012;139(1–3):66–72. [PubMed]
187. Gubert C, Stertz L, Pfaffenseller B, et al. Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. *Journal of Psychiatric Research*. 2013;47(10):1396–1402. [PubMed]
188. Costa A, Scholer-Dahirel A, Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. *Seminars in Cancer Biology*. 2014
189. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646–674. [PubMed]
190. Masoudi-Nejad A, Asgari Y. Metabolic Cancer Biology: structural-based analysis of cancer as a metabolic disease, new sights and opportunities for disease treatment. *Seminars in Cancer Biology*. 2014 [PubMed]
191. Soini Y, Haapasaari K, Vaarala MH, Turpeenniemi-Hujanen T, Kärjä V, Karihtala P. 8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma. *International Journal of Clinical and Experimental Pathology*. 2011;4(3):267–275. [PMC free article] [PubMed]
192. Badjatia N, Satyam A, Singh P, Seth A, Sharma A. Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. *Urologic Oncology: Seminars and Original Investigations*. 2010;28(4):360–367. [PubMed]
193. Guney AI, Ergec DS, Tavukcu HH, et al. Detection of mitochondrial DNA mutations in nonmuscle invasive bladder cancer. *Genetic Testing and Molecular Biomarkers*. 2012;16(7):672–678. [PubMed]
194. Niu HT, Yang CM, Jiang G, et al. Cancer stroma proteome expression profile of superficial bladder transitional cell carcinoma and biomarker discovery. *The Journal of Cancer Research and Clinical Oncology*. 2011;137(8):1273–1282. [PubMed]
195. Kedzierska M, Olas B, Wachowicz B, Jeziorski A, Piekarski J. Relationship between thiol, tyrosine nitration and carbonyl formation as biomarkers of oxidative stress and changes of hemostatic function of plasma from breast cancer patients before surgery. *Clinical Biochemistry*. 2012;45(3):231–236. [PubMed]
196. Pande D, Negi R, Karki K, et al. Oxidative damage markers as possible discriminatory biomarkers in breast carcinoma. *Translational Research*. 2012;160(6):411–418. [PubMed]
197. Martinez-Outschoorn UE, Balliet R, Lin Z, et al. BRCA1 mutations drive oxidative stress and

- glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. *Cell Cycle*. 2012;11(23):4402–4413. [PMC free article] [PubMed]
198. Salem AF, Howell A, Sartini M, et al. Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1 α , autophagy and ketone body production. *Cell Cycle*. 2012;11(22):4167–4173. [PMC free article] [PubMed]
 199. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, et al. Mitochondria, “fuel” breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cell. *Cell Cycle*. 2012;11(23):4390–4401. [PMC free article] [PubMed]
 200. Coene ED, Hollinshead MS, Waeytens AAT, et al. Phosphorylated BRCA1 is predominantly located in the nucleus and mitochondria. *Molecular Biology of the Cell*. 2005;16(2):997–1010. [PMC free article] [PubMed]
 201. Cooney RV, Dai Q, Gao Y, et al. Low plasma coenzyme Q(10) levels and breast cancer risk in Chinese women. *Cancer Epidemiology Biomarkers and Prevention*. 2011;20(6):1124–1130. [PMC free article] [PubMed]
 202. Looi M, Ahmad Zailani Hatta AZH, Dali AZHM, Ali SAM, Ngah WZW, Yusof YAM. Oxidative damage and antioxidant status in patients with cervical intraepithelial neoplasia and carcinoma of the cervix. *European Journal of Cancer Prevention*. 2008;17(6):555–560. [PubMed]
 203. Li L, Chen C, Cao Z, et al. Expression of peroxiredoxin III cervical lesions. *ZZhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi*. 2009;23(6):443–445. [PubMed]
 204. Srivastava S, Natu SM, Gupta A, et al. Lipid peroxidation and antioxidants in different stages of cervical cancer: prognostic significance. *Indian Journal of Cancer*. 2009;46(4):297–302. [PubMed]
 205. Sharma A, Rajappa M, Satyam A, Sharma M. Oxidant/anti-oxidant dynamics in patients with advanced cervical cancer: correlation with treatment response. *Molecular and Cellular Biochemistry*. 2010;341(1-2):65–72. [PubMed]
 206. de Marco F, Bucaj E, Foppoli C, et al. Oxidative stress in HPV-driven viral carcinogenesis: redox proteomics analysis of HPV-16 dysplastic and neoplastic tissues. *PLoS ONE*. 2012;7(3)e34366 [PMC free article] [PubMed]
 207. Gao L, Pan X, Li L, et al. Null genotypes of gstm1 and gstt1 contribute to risk of cervical neoplasia: an evidence-based meta-analysis. *PLoS ONE*. 2011;6(5)e20157 [PMC free article] [PubMed]
 208. Safaeian M, Hildesheim A, Gonzalez P, et al. Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer. *PLoS ONE*. 2012;7(4)e33619 [PMC free article] [PubMed]
 209. Strzelczyk JK, Wielkoszyński T, Krakowczyk Ł, et al. The activity of antioxidant enzymes in colorectal adenocarcinoma and corresponding normal mucosa. *Acta Biochimica Polonica*. 2012;59(4):549–556. [PubMed]
 210. Scarpa M, Cardin R, Bortolami M, et al. Mucosal immune environment in colonic carcinogenesis: CD80 expression is associated to oxidative DNA damage and TLR4-NF κ B signalling. *European Journal of Cancer*. 2013;49(1):254–263. [PubMed]
 211. Thyagarajan B, Wang R, Barcelo H, et al. Mitochondrial copy number is associated with colorectal cancer risk. *Cancer Epidemiology, Biomarkers and Prevention*. 2012;21(9):1574–1581. [PMC free article] [PubMed]
 212. Pejić S, Todorović A, Stojiljković V, et al. Antioxidant enzymes and lipid peroxidation in endometrium of patients with polyps, myoma, hyperplasia and adenocarcinoma. *Reproductive Biology and Endocrinology*. 2009;7(article 149) [PMC free article] [PubMed]
 213. Cormio A, Guerra F, Cormio G, et al. The PGC-1 α -dependent pathway of mitochondrial biogenesis is upregulated in type I endometrial cancer. *Biochemical and Biophysical Research Communications*. 2009;390(4):1182–1185. [PubMed]
 214. Guerra F, Kurelac I, Cormio A, et al. Placing mitochondrial DNA mutations within the progression

- model of type I endometrial carcinoma. *Human Molecular Genetics*. 2011;20(12):2394–2405. [PubMed]
215. Ni J, Mei M, Sun L. Oxidative DNA damage and repair in chronic atrophic gastritis and gastric cancer. *Hepato-Gastroenterology*. 2012;59(115):671–675. [PubMed]
 216. Uehara T, Ma D, Yao Y, et al. H. pylori infection is associated with DNA damage of Lgr5-positive epithelial stem cells in the stomach of patients with gastric cancer. *Digestive Diseases and Sciences*. 2013;58(1):140–149. [PMC free article] [PubMed]
 217. Machado AM, Desler C, Bøggild S, et al. Helicobacter pylori infection affects mitochondrial function and DNA repair, thus, mediating genetic instability in gastric cells. *Mechanisms of Ageing and Development*. 2013;134(10):460–466. [PubMed]
 218. Suzuki Y, Imai K, Takai K, et al. Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test. *The Journal of Cancer Research and Clinical Oncology*. 2013;139(5):845–852. [PubMed]
 219. Tanaka S, Miyanishi K, Kobune M, et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. *Journal of Gastroenterology*. 2013;48(11):1249–1258. [PubMed]
 220. Tamai T, Uto H, Takami Y, et al. Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma. *World Journal of Gastroenterology*. 2011;17(44):4890–4898. [PMC free article] [PubMed]
 221. Jin Y, Yu Q, Zhou D, et al. The mitochondrial DNA 9-bp deletion polymorphism is a risk factor for hepatocellular carcinoma in the Chinese population. *Genetic Testing and Molecular Biomarkers*. 2012;16(5):330–334. [PMC free article] [PubMed]
 222. Duan W, Hua R, Yi W, et al. The association between OGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis of 27 studies. *PLoS ONE*. 2012;7(4):e35970 [PMC free article] [PubMed]
 223. Cobanoglu U, Demir H, Cebi A, et al. Lipid peroxidation, DNA damage and coenzyme Q(10) in lung cancer patients—markers for risk assessment? *Asian Pacific Journal of Cancer Prevention*. 2011;12(6):1399–1403. [PubMed]
 224. Janik J, Swoboda M, Janowska B, et al. 8-Oxoguanine incision activity is impaired in lung tissues of NSCLC patients with the polymorphism of OGG1 and XRCC1 genes. *Mutation Research—Fundamental and Molecular Mechanisms of Mutagenesis*. 2011;709-710:21–31. [PubMed]
 225. Tsai JR, Wang HM, Liu PL, et al. High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. *Cell Oncology*. 2012;35(6):461–471. [PubMed]
 226. Ito K, Yano T, Morodomi Y, et al. Serum antioxidant capacity and oxidative injury to pulmonary DNA in never-smokers with primary lung cancer. *Anticancer Research*. 2012;32(3):1063–1067. [PubMed]
 227. Ye X, Li Q, Wang G, et al. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. *International Journal of Cancer*. 2011;129(4):820–831. [PubMed]
 228. Chae YC, Caino MC, Lisanti S, et al. Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. *Cancer Cell*. 2012;22(3):331–344. [PMC free article] [PubMed]
 229. Murtas D, Piras F, Minerba L, et al. Nuclear 8-hydroxy-2'-deoxyguanosine as survival biomarker in patients with cutaneous melanoma. *Oncology Reports*. 2010;23(2):329–335. [PubMed]
 230. Ibarrola-Villava M, Peña-Chilet M, Fernandez LP, et al. Genetic polymorphisms in DNA repair and oxidative stress pathways associated with malignant melanoma susceptibility. *European Journal of Cancer*. 2011;47(17):2618–2625. [PubMed]
 231. Lin X, Zheng W, Liu J, et al. Oxidative stress in malignant melanoma enhances Tumor Necrosis

- Factor- α secretion of tumor-associated macrophages that promote cancer cell invasion. *Antioxidants and Redox Signaling*. 2013;19(12):1337–1355. [PubMed]
232. Barbi de Moura M, Vincent G, Fayewicz SL, et al. Mitochondrial respiration—an important therapeutic target in melanoma. *PLoS ONE*. 2012;7(8):e40690 [PMC free article] [PubMed]
 233. Singh RK, Tripathi AK, Tripathi P, Singh S, Singh R, Ahmad R. Studies on biomarkers for oxidative stress in patients with chronic myeloid leukemia. *Hematology/Oncology and Stem Cell Therapy*. 2009;2(1):285–288. [PubMed]
 234. Sailaja K, Surekha D, Nageswara Rao D, Raghunadha Rao D, Vishnupriya S. Association of the GSTP1 gene (Ile105Val) Polymorphism with chronic myeloid leukemia. *Asian Pacific Journal of Cancer Prevention*. 2010;11(2):461–464. [PubMed]
 235. Ahmad R, Tripathi AK, Tripathi P, Singh R, Singh S, Singh RK. Studies on lipid peroxidation and non-enzymatic antioxidant status as indices of oxidative stress in patients with chronic myeloid leukaemia. *Singapore Medical Journal*. 2010;51(2):110–115. [PubMed]
 236. Zhou F, Zhang W, Wei Y, et al. Involvement of oxidative stress in the relapse of acute myeloid leukemia. *The Journal of Biological Chemistry*. 2010;285(20):15010–15015. [PMC free article] [PubMed]
 237. Palande KK, Beekman R, van der Meeren LE, Berna Beverloo H, Valk PJM, Touw IP. The antioxidant protein peroxiredoxin 4 is epigenetically down regulated in acute promyelocytic leukemia. *PLoS ONE*. 2011;6(1):e16340 [PMC free article] [PubMed]
 238. Akinlolu A, Akingbola T, Salau B. Lipid peroxidation in Nigerians affected with haematological malignancies. *African Journal of Medicine and Medical Sciences*. 2012;41(supplement):145–148. [PubMed]
 239. Boultonwood J, Fidler C, Mills KI, et al. Amplification of mitochondrial DNA in acute myeloid leukaemia. *British Journal of Haematology*. 1996;95(2):426–431. [PubMed]
 240. Koistinen P, Ruuska S, Säily M, et al. An association between manganese superoxide dismutase polymorphism and outcome of chemotherapy in acute myeloid leukemia. *Haematologica*. 2006;91(6):829–832. [PubMed]
 241. Schildgen V, Wulfert M, Gattermann N. Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes. *Experimental Hematology*. 2011;39(6):666.e1–675.e1. [PubMed]
 242. Gokul S, Patil VS, Jailkhani R, Hallikeri K, Kattappagari KK. Oxidant-antioxidant status in blood and tumor tissue of oral squamous cell carcinoma patients. *Oral Diseases*. 2010;16(1):29–33. [PubMed]
 243. Korde SD, Basak A, Chaudhary M, Goyal M, Vagga A. Enhanced nitrosative and oxidative stress with decreased total antioxidant capacity in patients with oral precancer and oral squamous cell carcinoma. *Oncology*. 2011;80(5-6):382–389. [PubMed]
 244. Marakala V, Malathi M, Shivashankara AR. Lipid peroxidation and antioxidant vitamin status in oral cavity and oropharyngeal cancer patients. *Asian Pacific Organization for Cancer Prevention*. 2012;13(11):5763–5765. [PubMed]
 245. Vlková B, Stanko P, Minárik G, et al. Salivary markers of oxidative stress in patients with oral premalignant lesions. *Archives of Oral Biology*. 2012;57(12):1651–1656. [PubMed]
 246. Liu S, Jiang R, Chen F, Wang W, Lin J. Somatic mutations in the D-loop of mitochondrial DNA in oral squamous cell carcinoma. *European Archives of Oto-Rhino-Laryngology*. 2012;269(6):1665–1670. [PubMed]
 247. Gasparre G, Porcelli AM, Bonora E, et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocyctic phenotype in thyroid tumors. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(21):9001–9006. [PMC free article] [PubMed]
 248. Bonora E, Porcelli AM, Gasparre G, et al. Defective oxidative phosphorylation in thyroid oncocyctic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III.

- Cancer Research. 2006;66(12):6087–6096. [PubMed]
249. Sciascia S, Roccatello D, Bertero MT, et al. 8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. *Inflammation Research*. 2012;61(8):809–816. [PubMed]
 250. Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. *Blood*. 2012;119(24):5859–5870. [PubMed]
 251. Naziroğlu M, Kökçam I, Simşek H, et al. Lipid peroxidation and antioxidants in plasma and red blood cells from patients with pemphigus vulgaris. *Journal of Basic and Clinical Physiology and Pharmacology*. 2003;14(1):31–42. [PubMed]
 252. Abida O, Ben Mansour R, Gargouri B, et al. Catalase and lipid peroxidation values in serum of Tunisian patients with pemphigus vulgaris and foliaceus. *Biological Trace Element Research*. 2012;150(1–3):74–80. [PubMed]
 253. Marchenko S, Chernyavsky AI, Arredondo J, Gindi V, Grando SA. Antimitochondrial autoantibodies in pemphigus vulgaris: a missing link in disease pathophysiology. *The Journal of Biological Chemistry*. 2010;285(6):3695–3704. [PMC free article] [PubMed]
 254. Kalantari-Dehaghi M, Chen Y, Deng W, et al. Mechanisms of mitochondrial damage in keratinocytes by pemphigus vulgaris antibodies. *The Journal of Biological Chemistry*. 2013;288(23):16916–16925. [PMC free article] [PubMed]
 255. Cash WJ, McCance DR, Young IS, et al. Primary biliary cirrhosis is associated with oxidative stress and endothelial dysfunction but not increased cardiovascular risk. *Hepatology Research*. 2010;40(11):1098–1106. [PubMed]
 256. Sorrentino P, Terracciano L, D'Angelo S, et al. Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis. *Journal of Gastroenterology*. 2010;45(10):1053–1062. [PubMed]
 257. Salunga TL, Cui Z, Shimoda S, et al. Oxidative stress-induced apoptosis of bile duct cells in primary biliary cirrhosis. *Journal of Autoimmunity*. 2007;29(2–3):78–86. [PubMed]
 258. Leung PSC, Rossaro L, Davis PA, et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. *Hepatology*. 2007;46(5):1436–1442. [PMC free article] [PubMed]
 259. Basavaraj KH, Vasu Devaraju P, Rao KS. Studies on serum 8-hydroxy guanosine (8-OHdG) as reliable biomarker for psoriasis. *Journal of the European Academy of Dermatology and Venereology*. 2013;27(5):655–657. [PubMed]
 260. Kaur S, Zilmer K, Leping V, et al. Serum methylglyoxal level and its association with oxidative stress and disease severity in patients with psoriasis. *Archives of Dermatological Research*. 2013;305(6):489–494. [PubMed]
 261. Barygina VV, Becatti M, Soldi G, et al. Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF- α therapy. *Redox Reports*. 2013;18(3):100–106. [PubMed]
 262. Gabr SA, Al-Ghadi AH. Role of cellular oxidative stress and cytochrome c in the pathogenesis of psoriasis. *Archives of Dermatological Research*. 2012;304(6):451–457. [PubMed]
 263. Stark K, Törmä H, Oliw EH. Co-localization of COX-2, CYP4F8, and mPGES-1 in epidermis with prominent expression of CYP4F8 mRNA in psoriatic lesions. *Prostaglandins and Other Lipid Mediators*. 2006;79(1–2):114–125. [PubMed]
 264. Shah D, Wanchu A, Bhatnagar A. Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. *Immunobiology*. 2011;216(9):1010–1017. [PubMed]
 265. Connor AM, Mahomed N, Gandhi R, Keystone EC, Berger SA. TNF α modulates protein degradation pathways in rheumatoid arthritis synovial fibroblasts. *Arthritis Research and Therapy*. 2012;14(2, article R62) [PMC free article] [PubMed]

266. Stamp LK, Khalilova I, Tarr JM, et al. Myeloperoxidase and oxidative stress in rheumatoid arthritis. *Rheumatology*. 2012;51(10):1796–1803. [PubMed]
267. Kundu S, Ghosh P, Datta S, et al. Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis. *Free Radical Research*. 2012;46(12):1482–1489. [PubMed]
268. Ahmad S, Habib S, Moinuddin A. Preferential recognition of epitopes on AGE-IgG by the autoantibodies in rheumatoid arthritis patients. *Human Immunology*. 2013;74(1):23–27. [PubMed]
269. Harty LC, Binińska M, O'Sullivan J, et al. Mitochondrial mutagenesis correlates with the local inflammatory environment in arthritis. *Annals of the Rheumatic Diseases*. 2012;71(4):582–588. [PubMed]
270. Norheim KB, Jonsson G, Harboe E, Hanasand M, Gøransson L, Omdal R. Oxidative stress, as measured by protein oxidation, is increased in primary Sjögren's syndrome. *Free Radical Research*. 2012;46(2):141–146. [PubMed]
271. Cay HF, Sezer I, Dogan S, et al. Polymorphism in the TNF- α gene promoter at position –1031 is associated with increased circulating levels of TNF- α , myeloperoxidase and nitrotyrosine in primary Sjögren's Syndrome. *Clinical and Experimental Rheumatology*. 2012;30(6):843–849. [PubMed]
272. Ryo K, Yamada H, Nakagawa Y, et al. Possible involvement of oxidative stress in salivary gland of patients with Sjögren's syndrome. *Pathobiology*. 2007;73(5):252–260. [PubMed]
273. Kurimoto C, Kawano S, Tsuji G, et al. Thioredoxin may exert a protective effect against tissue damage caused by oxidative stress in salivary glands of patients with Sjögren's syndrome. *The Journal of Rheumatology*. 2007;34(10):2035–2043. [PubMed]
274. Ikuno N, Mackay IR, Jois J, Omagari K, Rowley MJ. Antimitochondrial autoantibodies in saliva and sera from patients with primary biliary cirrhosis. *Journal of Gastroenterology and Hepatology*. 2001;16(12):1390–1394. [PubMed]
275. Fernandez D, Bonilla E, Phillips P, Perl A. Signaling abnormalities in systemic lupus erythematosus as potential drug targets. *Endocrine, Metabolic and Immune Disorders—Drug Targets*. 2006;6(4):305–311. [PubMed]
276. Perl A, Hanczko R, Doherty E. Assessment of mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus. *Methods in Molecular Biology*. 2012;900:61–89. [PubMed]
277. Hassan I, Sajad P, Majid S, et al. Serum antioxidant status in patients with systemic sclerosis. *Indian Journal of Dermatology*. 2013;58(3):p. 239. [PMC free article] [PubMed]
278. Zalewska A, Knaś M, Gińdzieńska-Sieśkiewicz E, et al. Salivary antioxidants in patients with systemic sclerosis. *Journal of Oral Pathology and Medicine*. 2013;43(1):61–68. [PubMed]
279. Cruz-Domínguez MP, Montes-Cortes DH, Olivares-Corichi IM, et al. Oxidative stress in Mexicans with diffuse cutaneous systemic sclerosis. *Rheumatology International*. 2013;33(9):2261–2267. [PubMed]
280. Ohtsuka T. Relation between elevated high-sensitivity C-reactive protein and anti-mitochondria antibody in patients with systemic sclerosis. *Journal of Dermatology*. 2008;35(2):70–75. [PubMed]
281. Kostyuk VA, Potapovich AI, Cesario E, et al. Dysfunction of glutathione S-transferase leads to excess 4-hydroxy-2-nonenal and H₂O₂ and impaired cytokine pattern in cultured keratinocytes and blood of vitiligo patients. *Antioxidants and Redox Signaling*. 2010;13(5):607–620. [PubMed]
282. Bassiouny DA, Khorshied MM. Glutathione S-transferase M1 and T1 genetic polymorphism in Egyptian patients with nonsegmental vitiligo. *Clinical and Experimental Dermatology*. 2013;38(2):160–163. [PubMed]
283. Dell'Anna ML, Ottaviani M, Bellei B, et al. Membrane lipid defects are responsible for the generation of reactive oxygen species in peripheral blood mononuclear cells from vitiligo patients. *Journal of Cellular Physiology*. 2010;223(1):187–193. [PubMed]
284. Heydari B, Kazemi T, Zarban A, et al. Correlation of cataract with serum lipids, glucose and antioxidant activities: a case-control study. *West Indian Medical Journal*. 2012;61(3):230–234.

- [PubMed]
285. Kisic B, Miric D, Zoric L, Ilic A, Dragojevic I. Antioxidant capacity of lenses with age-related cataract. *Oxidative Medicine and Cellular Longevity*. 2012;2012:8 pages.467130 [PMC free article] [PubMed]
 286. Zhang Y, Zhang L, Sun D, Li Z, Wang L, Liu P. Genetic polymorphisms of superoxide dismutases, catalase, and glutathione peroxidase in age-related cataract. *Molecular Vision*. 2011;17:2325–2332. [PMC free article] [PubMed]
 287. Jarrett SG, Lewin AS, Boulton ME. The importance of Mitochondria in age-related and inherited eye disorders. *Ophthalmic Research*. 2010;44(3):179–190. [PMC free article] [PubMed]
 288. Lee W, Wells T, Kantorow M. Localization and H(2)O(2)-specific induction of PRDX3 in the eye lens. *Molecular Vision*. 2007;13:1469–1474. [PubMed]
 289. Bagis S, Tamer L, Sahin G, et al. Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? *Rheumatology International*. 2005;25(3):188–190. [PubMed]
 290. Altindag O, Celik H. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. *Redox Report*. 2006;11(3):131–135. [PubMed]
 291. Cordero MD, Alcocer-Gómez E, Cano-García FJ, et al. Clinical symptoms in Fibromyalgia are better associated to lipid peroxidation levels in blood mononuclear cells rather than in plasma. *PLoS ONE*. 2011;6(10):e26915 [PMC free article] [PubMed]
 292. Cordero MD, de Miguel M, Moreno Fernández AM, et al. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. *Arthritis Research and Therapy*. 2010;12(1, article R17) [PMC free article] [PubMed]
 293. Cordero MD, Díaz-Parrado E, Carrión AM, et al. Is inflammation a mitochondrial dysfunction-dependent event in fibromyalgia? *Antioxidants and Redox Signaling*. 2013;18(7):800–807. [PMC free article] [PubMed]
 294. Običan S, Scialli AR. Teratogenic exposures. *American Journal of Medical Genetics C: Seminars in Medical Genetics*. 2011;157(3):150–169. [PubMed]
 295. Wells PG, Bhuller Y, Chen CS, et al. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. *Toxicology and Applied Pharmacology*. 2005;207(2, supplement):S354–S366. [PubMed]
 296. Kovacic P, Somanathan R. Mechanism of teratogenesis: electron transfer, reactive oxygen species, and antioxidants. *Birth Defects Research C—Embryo Today: Reviews*. 2006;78(4):308–325. [PubMed]
 297. Zheng X, Su M, Pei L, et al. Metabolic signature of pregnant women with neural tube defects in offspring. *Journal of Proteome Research*. 2011;10(10):4845–4854. [PubMed]
 298. Dong J, Sulik KK, Chen S. The role of NOX enzymes in ethanol-induced oxidative stress and apoptosis in mouse embryos. *Toxicology Letters*. 2010;193(1):94–100. [PMC free article] [PubMed]
 299. Fantel AG, Person RE. Involvement of mitochondria and other free radical sources in normal and abnormal fetal development. *Annals of the New York Academy of Sciences*. 2002;959:424–433. [PubMed]
 300. Xu Y, Liu P, Li Y. Impaired development of mitochondria plays a role in the central nervous system defects of fetal alcohol syndrome. *Birth Defects Research A—Clinical and Molecular Teratology*. 2005;73(2):83–91. [PubMed]
 301. Harman D. Aging: a theory based on free radical and radiation chemistry. *The Journal of Gerontology*. 1956;11(3):298–300. [PubMed]
 302. Harman D. Free radical theory of aging: dietary implications. *The American Journal of Clinical Nutrition*. 1972;25(8):839–843. [PubMed]
 303. Przyklenk K, Kloner RA. Effect of oxygen-derived free radical scavengers on infarct size following six hours of permanent coronary artery occlusion: salvage or delay of myocyte necrosis? *Basic Research in Cardiology*. 1987;82(2):146–158. [PubMed]
 304. Wolff SP, Bascall ZA, Hunt JV. 'Autooxidative glycosylation': free radicals and glycation theory.

- Progress in Clinical and Biological Research. 1989;304:259–275. [PubMed]
305. Clausen J. Demential syndromes and the lipid metabolism. *Acta Neurologica Scandinavica*. 1984;70(5):345–355. [PubMed]
 306. Zemlan FP, Thienhaus OJ, Bosmann HB. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation. *Brain Research*. 1989;476(1):160–162. [PubMed]
 307. Vives-Bauza C, Przedborski S. Mitophagy: the latest problem for Parkinson's disease. *Trends in Molecular Medicine*. 2011;17(3):158–165. [PubMed]
 308. Wołyniec E, Karpińska J, Losiewska S, et al. Determination of lipoic acid by flow-injection and high-performance liquid chromatography with chemiluminescence detection. *Talanta*. 2012;96:223–229. [PubMed]
 309. Pagano G, Castello G. Oxidative stress and mitochondrial dysfunction in down syndrome. *Advances in Experimental Medicine and Biology*. 2012;724:291–299. [PubMed]
 310. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. *Neurochemical Research*. 2008;33(1):194–203. [PubMed]
 311. Tarnopolsky MA. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. *Advanced Drug Delivery Reviews*. 2008;60(13-14):1561–1567. [PubMed]
 312. McMackin CJ, Widlansky ME, Hamburg NM, et al. Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. *Journal of Clinical Hypertension*. 2007;9(4):249–255. [PMC free article] [PubMed]
 313. Parikh S, Goldstein A, Koenig MK, et al. Practice patterns of mitochondrial disease physicians in North America, part 2: treatment, care and management. *Mitochondrion*. 2013;13(6):681–687. [PubMed]
 314. Pagano G, Aiello Talamanca A, Castello G, et al. Mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: current experience and rational design of chemoprevention trials. Submitted. [PMC free article] [PubMed]
 315. Richter C.C., Kass G.E. Oxidative stress in mitochondria: its relationship to cellular Ca²⁺ homeostasis, cell death, proliferation, and differentiation. *Chem. Biol. Interact*. 1991;77:1–23. doi: 10.1016/0009-2797(91)90002-O. [PubMed] [Cross Ref]
 316. Sohal R.S., Brunk U.T. Mitochondrial production of pro-oxidants and cellular senescence. *Mutat. Res./DNAging*. 1992;275:295–304. doi: 10.1016/0921-8734(92)90033-L. [PubMed] [Cross Ref]
 317. Di Monte D.A., Chan P., Sandy M.S. Glutathione in Parkinson's disease: A link between oxidative stress and mitochondrial damage? *Ann. Neurol*. 1992;32:S111–S115. [PubMed]
 318. Beal M.F. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. *Parkinsonism Relat. Disord*. 2009;15:S189–S194. doi: 10.1016/S1353-8020(09)70812-0. [PubMed] [Cross Ref]
 319. Mischley L.K., Allen J., Bradley R. Coenzyme Q10 deficiency in patients with Parkinson's disease. *J. Neurol. Sci*. 2012;318:72–75. doi: 10.1016/j.jns.2012.03.023. [PMC free article] [PubMed] [Cross Ref]
 320. Parikh S., Goldstein A., Koenig M.K., Scaglia F., Enns G.M., Saneto R., Mitochondrial Medicine Society Clinical Directors Working Group. Clinical Director's Work Group Practice patterns of mitochondrial disease physicians in North America. Part 2: Treatment, care and management. *Mitochondrion*. 2013;13:681–687. doi: 10.1016/j.mito.2013.09.003. [PubMed] [Cross Ref]
 321. Tarnopolsky M.A. The mitochondrial cocktail: Rationale for combined nutraceutical therapy in mitochondrial cytopathies. *Adv. Drug Deliv. Rev*. 2008;60:1561–1567. doi: 10.1016/j.addr.2008.05.001. [PubMed] [Cross Ref]
 322. Pallardó F.V., Lloret A., Lebel M., d'Ischia M., Cogger V.C., le Couteur D.G., Gadaleta M.N., Castello G., Pagano G. Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-

- Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. *Biogerontology*. 2010;11:401–419. doi: 10.1007/s10522-010-9269-4. [PubMed] [Cross Ref]
323. Pagano G., Aiello Talamanca A., Castello G., Cordero M.D., d'Ischia M., Gadaleta M.N., Pallardó F.V., Petrović S., Tiano L., Zatterale A. Oxidative stress and mitochondrial dysfunction across broad-ranging pathologies: Toward a rational design of chemoprevention strategies by means of mitochondrial nutrients. *Oxid. Med. Cell. Longev.* 2014;2014:541230. doi: 10.1155/2014/541230. [PMC free article] [PubMed] [Cross Ref]
 324. Marshall A.W., Graul R.S., Morgan M.Y., Sherlock S. Treatment of alcohol-related liver disease with thioctic acid: A six month randomised double-blind trial. *Gut*. 1982;23:1088–1093. doi: 10.1136/gut.23.12.1088. [PMC free article] [PubMed] [Cross Ref]
 325. Tanaka J., Tominaga R., Yoshitoshi M., Matsui K., Komori M., Sese A., Yasui H., Tokunaga K. Coenzyme Q10: The prophylactic effect on low cardiac output following cardiac valve replacement. *Ann. Thorac. Surg.* 1982;33:145–151. doi: 10.1016/S0003-4975(10)61900-5. [PubMed] [Cross Ref]
 326. Langsjoen P.H., Vadhanavikit S., Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. *Proc. Natl. Acad. Sci. USA*. 1985;82:4240–4244. doi: 10.1073/pnas.82.12.4240. [PMC free article] [PubMed] [Cross Ref]
 327. Ogasahara S., Nishikawa Y., Yorifuji S., Soga F., Nakamura Y., Takahashi M., Hashimoto S., Kono N., Tarui S. Treatment of Kearns–Sayre syndrome with coenzyme Q10. *Neurology*. 1986;36:45–53. doi: 10.1212/WNL.36.1.45. [PubMed] [Cross Ref]
 328. Scarlato G.N., Bresolin N.I., Moroni I., Doriguzzi C., Castelli E., Comi G., Angelini C., Carenzi A. Multicenter trial with ubidecarenone: Treatment of 44 patients with mitochondrial myopathies. *Rev. Neurol.* 1991;147:542–548. [PubMed]
 329. Mayr J.A., Zimmermann F.A., Fauth C., Bergheim C., Meierhofer D., Radmayr D., Zschocke J., Koch J., Sperl W. Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. *Am. J. Hum. Genet.* 2011;89:792–797. doi: 10.1016/j.ajhg.2011.11.011. [PMC free article] [PubMed] [Cross Ref]
 330. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: An overview. *Neurochem. Res.* 2008;33:194–203. doi: 10.1007/s11064-007-9403-0. [PubMed] [Cross Ref]
 331. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. *Neuro Endocrinol. Lett.* 2009;30:470–476. [PubMed]
 332. Tiano L., Busciglio J. Mitochondrial dysfunction and Down's syndrome: Is there a role for coenzyme Q10? *Biofactors*. 2011;37:386–392. doi: 10.1002/biof.184. [PubMed] [Cross Ref]
 333. Hardas S.S., Sultana R., Clark A.M., Beckett T.L., Szveda L.I., Murphy M.P., Butterfield D.A. Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. *Redox Biol.* 2013;1:80–85. doi: 10.1016/j.redox.2013.01.002. [PMC free article] [PubMed] [Cross Ref]
 334. Kähler W., Kuklinski B., Rühlmann C., Plötz C. Diabetes mellitus—A free radical-associated disease. Results of adjuvant antioxidant supplementation. *Z. Gesamte Inn. Med.* 1993;48:223–232. [PubMed]
 335. Jacob S., Henriksen E.J., Schiemann A.L., Simon I., Clancy D.E., Tritschler H.J., Jung W.I., Augustin H.J., Dietze G.J. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. *Arzneimittelforschung*. 1995;45:872–874. [PubMed]
 336. Ziegler D., Hanefeld M., Ruhnau K.J., Meissner H.P., Lobisch M., Schütte K., Gries F.A. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study) *Diabetologia*. 1995;38:1425–1433. doi: 10.1007/BF00400603. [PubMed] [Cross Ref]
 337. Ziegler D., Schatz H., Conrad F., Gries F.A., Ulrich H., Reichel G. Effects of treatment with the

- antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). *Deutsche Kardiologie Autonome Neuropathie. Diabetes Care.* 1997;20:369–373. doi: 10.2337/diacare.20.3.369. [PubMed] [Cross Ref]
338. Stokov I.A., Kozlova N.A., Mozolevskii IuV, Miasoedov S.P., Iakhno N.N. The efficacy of the intravenous administration of the trometamol salt of thioctic (alpha-lipoic) acid in diabetic neuropathy. *Zh. Nevrol. Psikiatr. Im. S. S. Korsakova.* 1999;99:18–22. [PubMed]
 339. Jacob S.P., Ruus P.R., Hermann R., Tritschler H.J., Maerker E., Renn W., Augustin H.J., Dietze G.J., Rett K. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: A placebo-controlled pilot trial. *Free Radic. Biol. Med.* 1999;27:309–314. doi: 10.1016/S0891-5849(99)00089-1. [PubMed] [Cross Ref]
 340. Ziegler D., Hanefeld M., Ruhnau K.J., Hasche H., Lobisch M., Schütte K., Kerum G., Malessa R. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III study). *ALADIN III Study Group. Alpha-lipoic acid in diabetic neuropathy. Diabetes Care.* 1999;22:1296–1301. doi: 10.2337/diacare.22.8.1296. [PubMed] [Cross Ref]
 341. Reljanovic M.G., Reichel G.K., Rett K., Lobisch M., Schuette K., Möller W., Tritschler H.J., Mehnert H. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). *Alpha lipoic acid in diabetic neuropathy. Free Radic. Res.* 1999;31:171–179. doi: 10.1080/10715769900300721. [PubMed] [Cross Ref]
 342. Ruhnau K.J., Meissner H.P., Finn J.R., Reljanovic M., Lobisch M., Schütte K., Nehrdich D., Tritschler H.J., Mehnert H., Ziegler D. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. *Diabet. Med.* 1999;16:1040–1043. doi: 10.1046/j.1464-5491.1999.00190.x. [PubMed] [Cross Ref]
 343. Negrişanu G., Roşu M., Bolte B., Lefter D., Dabelea D. Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy. *Rom. J. Intern. Med.* 1999;37:297–306. [PubMed]
 344. Androne L., Gavan N.A., Veresiu I.A., Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. *In Vivo.* 2000;14:327–330. [PubMed]
 345. Haak E., Usadel K.H., Kusterer K., Amini P., Frommeyer R., Tritschler H.J., Haak T. Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. *Exp. Clin. Endocrinol. Diabetes.* 2000;108:168–174. doi: 10.1055/s-2000-7739. [PubMed] [Cross Ref]
 346. Evans J.L., Heymann C.J., Goldfine I.D., Gavin L.A. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. *Endocr. Pract.* 2002;8:29–35. doi: 10.4158/EP.8.1.29. [PubMed] [Cross Ref]
 347. Ametov A.S., Barinov A., Dyck P.J., Hermann R., Kozlova N., Litchy W.J., Low P.A., Nehrdich D., Novosadova M., O'Brien P.C., et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY trial. *Diabetes Care.* 2003;26:770–776. doi: 10.2337/diacare.26.3.770. [PubMed] [Cross Ref]
 348. Hahm J.R., Kim B.J., Kim K.W. Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. *J. Diabetes Complicat.* 2004;18:79–85. doi: 10.1016/S1056-8727(03)00033-3. [PubMed] [Cross Ref]
 349. Ziegler D., Ametov A., Barinov A., Dyck P.J., Gurieva I., Low P.A., Munzel U., Yakhno N., Raz I., Novosadova M., et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. *Diabetes Care.* 2006;29:2365–2370. doi: 10.2337/dc06-1216. [PubMed] [Cross Ref]
 350. Kamenova P. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. *Hormones.* 2006;5:251–258. [PubMed]
 351. Liu F., Zhang Y., Yang M., Liu B., Shen Y.D., Jia W.P., Xiang K.S. Curative effect of alpha-lipoic acid on

- peripheral neuropathy in type 2 diabetes: A clinical study. *Zhonghua Yi Xue Za Zhi*. 2007;87:2706–2709. [PubMed]
352. Xiang G.D., Sun H.L., Zhao L.S., Hou J., Yue L., Xu L. The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance. *Clin. Endocrinol*. 2008;68:716–723. doi: 10.1111/j.1365-2265.2007.03099.x. [PubMed] [Cross Ref]
 353. Bureković A., Terzić M., Alajbegović S., Vukojević Z., Hadzić N. The role of alpha-lipoic acid in diabetic polyneuropathy treatment. *Bosn. J. Basic Med. Sci*. 2008;8:341–245. [PubMed]
 354. Heinisch B.B., Francesconi M., Mittermayer F., Schaller G., Gouya G., Wolzt M., Pleiner J. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: A placebo-controlled randomized trial. *Eur. J. Clin. Investig*. 2010;40:148–154. doi: 10.1111/j.1365-2362.2009.02236.x. [PubMed] [Cross Ref]
 355. Palacka P., Kucharska J., Murin J., Dostalova K., Okkelova A., Cizova M., Waczulikova I., Moricova S., Gvozdzakova A. Complementary therapy in diabetic patients with chronic complications: A pilot study. *Bratisl. Lek. Listy*. 2010;111:205–211. [PubMed]
 356. Gu X.M., Zhang S.S., Wu J.C., Tang Z.Y., Lu Z.Q., Li H., Liu C., Chen L., Ning G. Efficacy and safety of high-dose α -lipoic acid in the treatment of diabetic polyneuropathy. *Zhonghua Yi Xue Za Zhi*. 2010;90:2473–2476. [PubMed]
 357. Xiang G., Pu J., Yue L., Hou J., Sun H. α -Lipoic acid can improve endothelial dysfunction in subjects with impaired fasting glucose. *Metabolism*. 2011;60:480–485. doi: 10.1016/j.metabol.2010.04.011. [PubMed] [Cross Ref]
 358. De Oliveira A.M., Rondó P.H., Luzia L.A., D'Abronzio F.H., Illison V.K. The effects of lipoic acid and α -tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial. *Diabetes Res. Clin. Pract*. 2011;92:253–260. doi: 10.1016/j.diabres.2011.02.010. [PubMed] [Cross Ref]
 359. Ansar H., Mazloom Z., Kazemi F., Hejazi N. Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. *Saudi Med. J*. 2011;32:584–588. [PubMed]
 360. Ziegler D., Low P.A., Litchy W.J., Boulton A.J., Vinik A.I., Freeman R., Samigull R., Tritschler H., Munzel U., Maus J., et al. Efficacy and safety of antioxidant treatment with α -lipoic acid over 4 years in diabetic polyneuropathy: The NATHAN 1 trial. *Diabetes Care*. 2011;34:2054–2060. doi: 10.2337/dc11-0503. [PMC free article] [PubMed] [Cross Ref]
 361. Haritoglou C., Gerss J., Hammes H.P., Kampik A., Ulbig M.W., RETIPON Study Group Alpha-lipoic acid for the prevention of diabetic macular edema. *Ophthalmologica*. 2011;226:127–137. doi: 10.1159/000329470. [PubMed] [Cross Ref]
 362. Rahman S.T., Merchant N., Haque T., Wahi J., Bhaheetharan S., Ferdinand K.C., Khan B.V. The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension: Results from the QUALITY study. *J. Cardiovasc. Pharmacol. Ther*. 2012;17:139–145. doi: 10.1177/1074248411413282. [PubMed] [Cross Ref]
 363. Bertolotto F., Massone A. Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathy. *Drugs R&D*. 2012;12:29–34. doi: 10.2165/11599200-000000000-00000. [PMC free article] [PubMed] [Cross Ref]
 364. Porasuphatana S., Suddee S., Nartnampong A., Konsil J., Harnwong B., Santaweek A. Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: A randomized double-blinded placebo-controlled study. *Asia Pac. J. Clin. Nutr*. 2012;21:12–21. [PubMed]
 365. Ibrahimasic K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment. *Med. Arch*. 2013;67:7–9. doi: 10.5455/medarh.2013.67.7-9. [PubMed] [Cross Ref]
 366. Tankova T., Koev D., Dakovska L. Alpha-lipoic acid in the treatment of autonomic diabetic

- neuropathy (controlled, randomized, open-label study) *Rom. J. Intern. Med.* 2004;42:457–464. [PubMed]
367. Huang E.A., Gitelman S.E. The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. *Pediat. Diabetes.* 2008;9:69–73. doi: 10.1111/j.1399-5448.2007.00342.x. [PubMed] [Cross Ref]
 368. Mollo R., Zaccardi F., Scalone G., Scavone G., Rizzo P., Navarese E.P., Manto A., Pitocco D., Lanza G.A., Ghirlanda G., et al. Effect of α -lipoic acid on platelet reactivity in type 1 diabetic patients. *Diabetes Care.* 2012;35:196–197. doi: 10.2337/dc11-1255. [PMC free article] [PubMed] [Cross Ref]
 369. Morcos M., Borcea V., Isermann B., Gehrke S., Ehret T., Henkels M., Schiekofer S., Hofmann M., Amiral J., Tritschler H., et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: An exploratory study. *Diabetes Res. Clin. Pract.* 2001;5:175–183. doi: 10.1016/S0168-8227(01)00223-6. [PubMed] [Cross Ref]
 370. Noori N., Tabibi H., Hosseiniapanah F., Hedayati M., Nafar M. Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy. *Int. J. Vitam. Nutr. Res.* 2013;83:77–85. doi: 10.1024/0300-9831/a000147. [PubMed] [Cross Ref]
 371. Hegazy S.K., Tolba O.A., Mostafa T.M., Eid M.A., el-Afify D.R. Alpha-lipoic acid improves subclinical left ventricular dysfunction in asymptomatic patients with type 1 diabetes. *Rev. Diabet. Stud.* 2013;10:58–67. doi: 10.1900/RDS.2013.10.58. [PMC free article] [PubMed] [Cross Ref]
 372. Huang Z., Wan X., Liu J., Deng W., Chen A., Liu L., Liu J., Wei G., Li H., Fang D., et al. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α -lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. *Diabetes Technol. Ther.* 2013;15:859–869. doi: 10.1089/dia.2013.0013. [PMC free article] [PubMed] [Cross Ref]
 373. Mitkov M.D., Aleksandrova I.Y., Orbetzova M.M. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. *Folia Med.* 2013;55:55–63. [PubMed]
 374. Pop-Busui R., Stevens M.J., Raffel D.M., White E.A., Mehta M., Plunkett C.D., Brown M.B., Feldman E.L. Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: A randomized controlled trial. *Diabetologia.* 2013;56:1835–1844. doi: 10.1007/s00125-013-2942-9. [PMC free article] [PubMed] [Cross Ref]
 375. Zhang X., Zhang Y., Gao X., Wu J., Jiao X., Zhao J., Lv X. Investigating the role of backward walking therapy in alleviating plantar pressure of patients with diabetic peripheral neuropathy. *Arch. Phys. Med. Rehabil.* 2014;95:832–839. doi: 10.1016/j.apmr.2014.01.003. [PubMed] [Cross Ref]
 376. Yadav V., Marracci G., Lovera J., Woodward W., Bogardus K., Marquardt W., Shinto L., Morris C., Bourdette D. Lipoic acid in multiple sclerosis: A pilot study. *Mult. Sclerosis.* 2005;11:159–165. doi: 10.1191/1352458505ms1143oa. [PubMed] [Cross Ref]
 377. Khalili M., Azimi A., Izadi V., Eghtesadi S., Mirshafiey A., Sahraian M.A., Motevalian A., Norouzi A., Sanoobar M., Eskandari G., et al. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: A double-blind, placebo-controlled, randomized clinical trial. *Neuroimmunomodulation.* 2014;21:291–296. doi: 10.1159/000356145. [PubMed] [Cross Ref]
 378. Bae S.C., Jung W.J., Lee E.J., Yu R., Sung M.K. Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease severity of rheumatoid arthritis patients. *J. Am. Coll. Nutr.* 2009;28:56–62. doi: 10.1080/07315724.2009.10719762. [PubMed] [Cross Ref]
 379. Galasko D.R., Peskind E., Clark C.M., Quinn J.F., Ringman J.M., Jicha G.A., Cotman C., Cottrell B., Montine T.J., Thomas R.G., et al. Alzheimer's disease cooperative study. Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures. *Arch. Neurol.* 2012;69:836–841. [PMC free article] [PubMed]
 380. Magis D., Ambrosini A., Sándor P., Jacquy J., Laloux P., Schoenen J. A randomized double-blind

- placebo-controlled trial of thioctic acid in migraine prophylaxis. *Headache*. 2007;47:52–57. doi: 10.1111/j.1526-4610.2006.00626.x. [PubMed] [Cross Ref]
381. Di Geronimo G., Caccese A.F., Caruso L., Soldati A., Passaretti U. Treatment of carpal tunnel syndrome with alpha-lipoic acid. *Eur. Rev. Med. Pharmacol. Sci.* 2009;13:133–139. [PubMed]
 382. Memeo A., Loiero M. Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: A randomized, double-blind, comparative study. *Clin. Drug Investig.* 2008;28:495–500. doi: 10.2165/00044011-200828080-00004. [PubMed] [Cross Ref]
 383. Ranieri M., Sciuscio M., Cortese A.M., Santamato A., di Teo L., Ianieri G., Bellomo R.G., Stasi M., Megna M. The use of alpha-lipoic acid (ALA), gamma linolenic acid (GLA) and rehabilitation in the treatment of back pain: Effect on health-related quality of life. *Int. J. Immunopathol. Pharmacol.* 2009;22:45–50. [PubMed]
 384. Shinto L., Quinn J., Montine T., Dodge H.H., Woodward W., Baldauf-Wagner S., Waichunas D., Bumgarner L., Bourdette D., Silbert L., et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. *J. Alzheimers Dis.* 2014;38:111–120. [PMC free article] [PubMed]
 385. Dünschede F., Erbes K., Kircher A., Westermann S., Seifert J., Schad A., Oliver K., Kierner A.K., Theodor J. Reduction of ischemia reperfusion injury after liver resection and hepatic inflow occlusion by alpha-lipoic acid in humans. *World J. Gastroenterol.* 2006;12:6812–6817. [PMC free article] [PubMed]
 386. Melhem A., Stern M., Shibolet O., Israeli E., Ackerman Z., Pappo O., Hemed N., Rowe M., Ohana H., Zabrecky G., et al. Treatment of chronic hepatitis C virus infection via antioxidants: Results of a phase I clinical trial. *J. Clin. Gastroenterol.* 2005;39:737–742. doi: 10.1097/01.mcg.0000174023.73472.29. [PubMed] [Cross Ref]
 387. Koh E.H., Lee W.J., Lee S.A., Kim E.H., Cho E.H., Jeong E., Kim D.W., Kim M.S., Park J.Y., Park K.G., et al. Effects of alpha-lipoic acid on body weight in obese subjects. *Am. J. Med.* 2011;124:85.e1-8. doi: 10.1016/j.amjmed.2010.08.005. [PubMed] [Cross Ref]
 388. McNeilly A.M., Davison G.W., Murphy M.H., Nadeem N., Trinick T., Duly E., Novials A., McEneny J. Effect of α -lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance. *Lipids Health Dis.* 2011;10:217. doi: 10.1186/1476-511X-10-217. [PMC free article] [PubMed] [Cross Ref]
 389. Zhang Y., Han P., Wu N., He B., Lu Y., Li S., Liu Y., Zhao S., Liu L., Li Y. Amelioration of lipid abnormalities by α -lipoic acid through antioxidative and anti-inflammatory effects. *Obesity*. 2011;19:1647–1653. doi: 10.1038/oby.2011.121. [PubMed] [Cross Ref]
 390. Skroza N., Proietti I., Bernardini N., la Viola G., Nicolucci F., Pampena R., Tolino E., Zuber S., Mancini M.T., Soccodato V., et al. Efficacy of food supplement to improve metabolic syndrome parameters in patients affected by moderate to severe psoriasis during anti-TNF α treatment. *G. Ital. Dermatol. Venereol.* 2013;148:661–665. [PubMed]
 391. Manning P.J., Sutherland W.H., Williams S.M., Walker R.J., Berry E.A., de Jong S.A., Ryalls A.R. The effect of lipoic acid and vitamin E therapies in individuals with the metabolic syndrome. *Nutr. Metab. Cardiovasc. Dis.* 2013;23:543–549. doi: 10.1016/j.numecd.2011.11.006. [PubMed] [Cross Ref]
 392. McMackin C.J., Widlansky M.E., Hamburg N.M. Effect of combined treatment with alpha-lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. *J. Clin. Hypertens.* 2007;9:249–255. doi: 10.1111/j.1524-6175.2007.06052.x. [PMC free article] [PubMed] [Cross Ref]
 393. Li R.J., Ji W.Q., Pang J.J., Wang J.L., Chen Y.G., Zhang Y. Alpha-lipoic acid ameliorates oxidative stress by increasing aldehyde dehydrogenase-2 activity in patients with acute coronary syndrome. *Tohoku J. Exp. Med.* 2013;229:45–51. doi: 10.1620/tjem.229.45. [PubMed] [Cross Ref]
 394. Vincent H.K., Bourguignon C.M., Vincent K.R., Taylor A.G. Effects of alpha-lipoic acid

- supplementation in peripheral arterial disease: A pilot study. *J. Altern. Complement. Med.* 2007;13:577–584. doi: 10.1089/acm.2007.6177. [PubMed] [Cross Ref]
395. Leong J.Y., van der Merwe J., Pepe S., Bailey M., Perkins A., Lymbury R., Esmore D., Marasco S., Rosenfeldt F. Perioperative metabolic therapy improves redox status and outcomes in cardiac surgery patients: A randomised trial. *Heart Lung Circ.* 2010;19:584–591. doi: 10.1016/j.hlc.2010.06.659. [PubMed] [Cross Ref]
 396. Chang J.W., Lee E.K., Kim T.H., Min W.K., Chun S., Lee K.U., Kim S.B., Park J.S. Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: A pilot study. *Am. J. Nephrol.* 2007;27:70–74. doi: 10.1159/000099035. [PubMed] [Cross Ref]
 397. Ramos L.F., Kane J., McMonagle E., Le P., Wu P., Shintani A., Ikizler T.A., Himmelfarb J. Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease. *J. Ren. Nutr.* 2011;21:211–218. doi: 10.1053/j.jrn.2010.08.003. [PMC free article] [PubMed] [Cross Ref]
 398. Khabbazi T., Mahdavi R., Safa J., Pour-Abdollahi P. Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis. *J. Ren. Nutr.* 2012;22:244–250. doi: 10.1053/j.jrn.2011.06.005. [PubMed] [Cross Ref]
 399. Himmelfarb J., Ikizler T.A., Ellis C., Wu P., Shintani A., Dalal S., Kaplan M., Chonchol M., Hakim R.M. Provision of antioxidant therapy in hemodialysis (PATH): A randomized clinical trial. *J. Am. Soc. Nephrol.* 2014;25:623–633. doi: 10.1681/ASN.2013050545. [PMC free article] [PubMed] [Cross Ref]
 400. Lott I.T., Doran E., Nguyen V.Q., Tournay A., Head E., Gillen D.L. Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation. *Am. J. Med. Genet. A.* 2011;155A:1939–1948. doi: 10.1002/ajmg.a.34114. [PMC free article] [PubMed] [Cross Ref]
 401. Martins V.D., Manfredini V., Peralba M.C., Benfato M.S. Alpha-lipoic acid modifies oxidative stress parameters in sickle cell trait subjects and sickle cell patients. *Clin. Nutr.* 2009;28:192–197. doi: 10.1016/j.clnu.2009.01.017. [PubMed] [Cross Ref]
 402. Rodriguez M.C., MacDonald J.R., Mahoney D.J., Parise G., Beal M.F., Tarnopolsky M.A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. *Muscle Nerve.* 2007;35:235–242. doi: 10.1002/mus.20688. [PubMed] [Cross Ref]
 403. Femiano F., Gombos F., Scully C., Busciolano M., de Luca P. Burning mouth syndrome (BMS): Controlled open trial of the efficacy of alpha-lipoic acid (thioctic acid) on symptomatology. *Oral Dis.* 2000;6:274–277. doi: 10.1111/j.1601-0825.2000.tb00138.x. [PubMed] [Cross Ref]
 404. Carbone M., Pentenero M., Carrozzo M., Ippolito A., Gandolfo S. Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: A double-blind, randomized, placebo-controlled study. *Eur. J. Pain.* 2009;13:492–496. doi: 10.1016/j.ejpain.2008.06.004. [PubMed] [Cross Ref]
 405. López-Jornet P., Camacho-Alonso F., Leon-Espinosa S. Efficacy of alpha lipoic acid in burning mouth syndrome: A randomized, placebo-treatment study. *J. Oral. Rehabil.* 2009;36:52–57. doi: 10.1111/j.1365-2842.2008.01914.x. [PubMed] [Cross Ref]
 406. Marino R., Torretta S., Capaccio P., Pignataro L., Spadari F. Different therapeutic strategies for burning mouth syndrome: Preliminary data. *J. Oral Pathol. Med.* 2010;39:611–616. doi: 10.1111/j.1600-0714.2010.00922.x. [PubMed] [Cross Ref]
 407. López-D'Alessandro E., Escovich L. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial. *Med. Oral Patol. Oral Cir. Bucal.* 2011;16:e635–e640. doi: 10.4317/medoral.16942. [PubMed] [Cross Ref]
 408. Mantovani G., Macciò A., Madeddu C., Gramignano G., Lusso M.R., Serpe R., Massa E., Astara G., Deiana L. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety

- in patients with cancer-related anorexia/cachexia and oxidative stress. *Cancer Epidemiol. Biomark. Prev.* 2006;15:1030–1034. doi: 10.1158/1055-9965.EPI-05-0538. [PubMed] [Cross Ref]
409. Mantovani G., Macciò A., Madeddu C., Gramignano G., Serpe R., Massa E., Dessì M., Tanca F.M., Sanna E., Deiana L., et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: Interim results. *Nutrition.* 2008;24:305–313. doi: 10.1016/j.nut.2007.12.010. [PubMed] [Cross Ref]
 410. Jariwalla R.J., Lalezari J., Cenko D., Mansour S.E., Kumar A., Gangapurkar B., Nakamura D. Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection. *J. Altern. Complement. Med.* 2008;14:139–146. doi: 10.1089/acm.2006.6397. [PubMed] [Cross Ref]
 411. Milazzo L., Menzaghi B., Caramma I., Nasi M., Sangaletti O., Cesari M., Zanone Poma B., Cossarizza A., Antinori S., Galli M. Effect of antioxidants on mitochondrial function in HIV-1-related lipodystrophy: A pilot study. *AIDS Res. Hum. Retroviruses.* 2010;26:1207–1214. doi: 10.1089/aid.2010.0024. [PubMed] [Cross Ref]
 412. Dell’Anna M.L., Mastrofrancesco A., Sala R., Venturini M., Ottaviani M., Vidolin A.P., Leone G., Calzavara P.G., Westerhof W., Picardo M. Antioxidants and narrow band-UVB in the treatment of vitiligo: A double-blind placebo controlled trial. *Clin. Exp. Dermatol.* 2007;32:631–636. doi: 10.1111/j.1365-2230.2007.02514.x. [PubMed] [Cross Ref]
 413. Mainini G., Rotondi M., di Nola K., Pezzella M.T., Iervolino S.A., Seguino E., D’Eufemia D., Iannicelli I., Torella M. Oral supplementation with antioxidant agents containing alpha lipoic acid: Effects on postmenopausal bone mass. *Clin. Exp. Obstet. Gynecol.* 2012;39:489–493. [PubMed]
 414. Garrido-Maraver J., Cordero M.D., Oropesa-Avila M., Oropesa-Avila M., Vega A.F., de la Mata M., Pavon A.D., Alcocer-Gomez E., Calero C.P., Paz M.V., et al. Clinical applications of coenzyme Q10. *Front. Biosci.* 2014;19:619–633. doi: 10.2741/4231. [Cross Ref]
 415. Singh R.B., Niaz M.A. Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: Discovery of a new role. *Int. J. Cardiol.* 1999;68:23–29. doi: 10.1016/S0167-5273(98)00323-4. [PubMed] [Cross Ref]
 416. Singh R.B., Niaz M.A., Rastogi S.S., Shukla P.K., Thakur A.S. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. *J. Hum. Hypertens.* 1999;13:203–208. doi: 10.1038/sj.jhh.1000778. [PubMed] [Cross Ref]
 417. Tiano L., Belardinelli R., Carnevali P., Principi F., Seddaiu G., Littarru G.P. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: A double-blind, randomized controlled study. *Eur. Heart J.* 2007;28:2249–2255. doi: 10.1093/eurheartj/ehm267. [PubMed] [Cross Ref]
 418. Belardinelli R., Muçaj A., Lacalaprince F., Solenghi M., Principi F., Tiano L., Littarru G.P. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. *Biofactors.* 2005;25:137–145. doi: 10.1002/biof.5520250115. [PubMed] [Cross Ref]
 419. Dai Y.L., Luk T.H., Yiu K.H., Wang M., Yip P.M., Lee S.W., Li S.W., Tam S., Fong B., Lau C.P., et al. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: A randomized controlled trial. *Atherosclerosis.* 2011;216:395–401. doi: 10.1016/j.atherosclerosis.2011.02.013. [PubMed] [Cross Ref]
 420. Lee B.J., Huang Y.C., Chen S.J., Lin P.T. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease. *Nutrition.* 2012;28:250–255. doi: 10.1016/j.nut.2011.06.004. [PubMed] [Cross Ref]
 421. Hofman-Bang C., Rehnqvist N., Swedberg K., Wiklund I., Aström H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. *J. Card. Fail.* 1995;1:101–107. doi: 10.1016/1071-9164(95)90011-X. [PubMed] [Cross Ref]
 422. Munkholm H., Hansen H.H., Rasmussen K. Coenzyme Q10 treatment in serious heart failure.

- Biofactors. 1999;9:285–289. doi: 10.1002/biof.5520090225. [PubMed] [Cross Ref]
423. Khatta M., Alexander B.S., Krichten C.M., Fisher M.L., Freudenberger R., Robinson S.W., Gottlieb S.S. The effect of coenzyme Q10 in patients with congestive heart failure. *Ann. Intern. Med.* 2000;132:636–640. doi: 10.7326/0003-4819-132-8-200004180-00006. [PubMed] [Cross Ref]
424. Berman M., Erman A., Ben-Gal T., Dvir D., Georgiou G.P., Stamler A., Vered Y., Vidne B.A., Aravot D. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: A randomized, placebo-controlled study. *Clin. Cardiol.* 2004;27:295–299. doi: 10.1002/clc.4960270512. [PubMed] [Cross Ref]
425. Damian M.S., Ellenberg D., Gildemeister R., Lauermann J., Simonis G., Sauter W., Georgi C. Coenzyme Q10 combined with mild hypothermia after cardiac arrest: A preliminary study. *Circulation.* 2004;110:3011–3016. doi: 10.1161/01.CIR.0000146894.45533.C2. [PubMed] [Cross Ref]
426. Witte K.K., Nikitin N.P., Parker A.C., von Haehling S., Volk H.D., Anker S.D., Clark A.L., Cleland J.G. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. *Eur. Heart J.* 2005;26:2238–2244. doi: 10.1093/eurheartj/ehi442. [PubMed] [Cross Ref]
427. Langsjoen P.H., Langsjoen A.M. Supplemental ubiquinol in patients with advanced congestive heart failure. *Biofactors.* 2008;32:119–128. doi: 10.1002/biof.5520320114. [PubMed] [Cross Ref]
428. Kumar A., Singh R.B., Saxena M., Niaz M.A., Josh S.R., Chattopadhyay P., Mechirova V., Pella D., Fedacko J. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. *Acta Cardiol.* 2007;62:349–354. doi: 10.2143/AC.62.4.2022278. [PubMed] [Cross Ref]
429. Belcaro G., Cesarone M.R., Dugall M., Hosoi M., Ippolito E., Bavera P., Grossi M.G. Investigation of pycnogenol in combination with coenzyme Q10 in heart failure patients (NYHA II/III) *Panminerva Med.* 2010;52:21–25. [PubMed]
430. Fumagalli S., Fattirolli F., Guarducci L., Cellai T., Baldasseroni S., Tarantini F., di Bari M., Masotti G., Marchionni N. Coenzyme Q10 terclatrate and creatine in chronic heart failure: A randomized, placebo-controlled, double-blind study. *Clin. Cardiol.* 2011;34:211–217. doi: 10.1002/clc.20846. [PubMed] [Cross Ref]
431. Kuklinski B., Weissenbacher E., Fähnrich A. Coenzyme Q10 and antioxidants in acute myocardial infarction. *Mol. Aspects Med.* 1994;15:s143–s147. doi: 10.1016/0098-2997(94)90023-X. [PubMed] [Cross Ref]
432. Singh R.B., Wander G.S., Rastogi A., Shukla P.K., Mittal A., Sharma J.P., Mehrotra S.K., Kapoor R., Chopra R.K. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. *Cardiovasc. Drugs Ther.* 1998;12:347–353. doi: 10.1023/A:1007764616025. [PubMed] [Cross Ref]
433. Singh R.B., Neki N.S., Kartikey K., Pella D., Kumar A., Niaz M.A., Thakur A.S. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. *Mol. Cell. Biochem.* 2003;246:75–82. doi: 10.1023/A:1023408031111. [PubMed] [Cross Ref]
434. Permanetter B., Rössy W., Klein G., Weingartner F., Seidl K.F., Blömer H. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. *Eur. Heart J.* 1992;13:1528–1533. [PubMed]
435. Langsjoen P.H., Folkers K., Lyson K., Muratsu K., Lyson T., Langsjoen P. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. *Int. J. Tissue React.* 1990;12:163–168. [PubMed]
436. Morisco C., Trimarco B., Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: A long-term multicenter randomized study. *Clin. Investig.* 1993;71:S134–S136. doi: 10.1007/BF00226854. [PubMed] [Cross Ref]
437. Ma A.W., Zhang W., Liu Z. Effect of protection and repair of injury of mitochondrial membrane-phospholipid on prognosis in patients with dilated cardiomyopathy. *Blood Press. Suppl.* 1.

- 1996;3:53–55. [PubMed]
438. Sacher H.L., Sacher M.L., Landau S.W., Kersten R., Dooley F., Sacher A., Sacher M., Dietrick K., Ichkhan K. The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. *Am. J. Ther.* 1997;4:66–72. doi: 10.1097/00045391-199702000-00003. [PubMed] [Cross Ref]
439. Soongswang J., Sangtawesin C., Durongpisitkul K., Laohaprasitiporn D., Nana A., Punlee K., Kangkagate C. The effect of coenzyme Q10 on idiopathic chronic dilated cardiomyopathy in children. *Pediatr. Cardiol.* 2005;26:361–366. doi: 10.1007/s00246-004-0742-1. [PubMed] [Cross Ref]
440. Caso G., Kelly P., McNurlan M.A., Lawson W.E. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. *Am. J. Cardiol.* 2007;99:1409–1412. doi: 10.1016/j.amjcard.2006.12.063. [PubMed] [Cross Ref]
441. Kocharian A., Shabani R., Rafiei-Khorgami M., Kiani A., Heidari-Bateni G. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. *Cardiol. Young.* 2009;19:501–506. doi: 10.1017/S1047951109990795. [PubMed] [Cross Ref]
442. Shargorodsky M., Debby O., Matas Z., Zimlichman R. Effect of long-term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors. *Nutr. Metab.* 2010;7:55. doi: 10.1186/1743-7075-7-55. [PMC free article] [PubMed] [Cross Ref]
443. Judy W.V., Stogsdill W.W., Folkers K. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. *Clin. Investig.* 1993;71:S155–S161. doi: 10.1007/BF00226859. [PubMed] [Cross Ref]
444. Taggart D.P., Jenkins M., Hooper J., Hadjinikolas L., Kemp M., Hue D., Bennett G. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. *Ann. Thorac. Surg.* 1996;61:829–833. doi: 10.1016/0003-4975(95)01120-X. [PubMed] [Cross Ref]
445. Chello M., Mastroberto P., Romano R., Castaldo P., Bevacqua E., Marchese A.R. Protection by coenzyme Q10 of tissue reperfusion injury during abdominal aortic cross-clamping. *J. Cardiovasc. Surg.* 1996;37:229–235. [PubMed]
446. Zhou M., Zhi Q., Tang Y., Yu D., Han J. Effects of coenzyme Q10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro. *J. Cardiovasc. Surg.* 1999;40:355–361. [PubMed]
447. Rosenfeldt F., Marasco S., Lyon W., Wowk M., Sheeran F., Bailey M., Esmore D., Davis B., Pick A., Rabinov M., et al. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. *J. Thorac. Cardiovasc. Surg.* 2005;129:25–32. doi: 10.1016/j.jtcvs.2004.03.034. [PubMed] [Cross Ref]
448. Keith M., Mazer C.D., Mikhail P., Jeejeebhoy F., Briet F., Errett L. Coenzyme Q10 in patients undergoing (coronary artery bypass graft) CABG: Effect of statins and nutritional supplementation. *Nutr. Metab. Cardiovasc. Dis.* 2008;18:105–111. doi: 10.1016/j.numecd.2006.09.011. [PubMed] [Cross Ref]
449. Makhija N., Sendasgupta C., Kiran U., Lakshmy R., Hote M.P., Choudhary S.K., Airan B., Abraham R. The role of oral coenzyme Q10 in patients undergoing coronary artery bypass graft surgery. *J. Cardiothorac. Vasc. Anesth.* 2008;22:832–839. doi: 10.1053/j.jvca.2008.03.007. [PubMed] [Cross Ref]
450. Alehagen U., Johansson P., Björnstedt M., Rosén A., Dahlström U. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. *Int. J. Cardiol.* 2013;167:1860–1866. doi: 10.1016/j.ijcard.2012.04.156. [PubMed] [Cross Ref]
451. Miles M.V., Patterson B.J., Chalfonte-Evans M.L., Horn P.S., Hickey F.J., Schapiro M.B., Steele P.E., Tang P.H., Hotze S.L. Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. *Pediatr. Neurol.* 2007;37:398–403. doi:

- 10.1016/j.pediatrneurol.2007.08.003. [PubMed] [Cross Ref]
452. Tiano L., Padella L., Santoro L., Carnevali P., Principi F., Brugè F., Gabrielli O., Littarru G.P. Prolonged coenzyme Q10 treatment in Down syndrome patients: Effect on DNA oxidation. *Neurobiol. Aging*. 2012;33:626.e1-8. doi: 10.1016/j.neurobiolaging.2011.03.025. [PubMed] [Cross Ref]
453. Sparaco M., Gaeta L.M., Santorelli F.M., Passarelli C., Tozzi G., Bertini E., Simonati A., Scaravilli F., Taroni F., Duyckaerts C., et al. Friedreich's ataxia: Oxidative stress and cytoskeletal abnormalities. *J. Neurol. Sci.* 2009;287:111–118. doi: 10.1016/j.jns.2009.08.052. [PubMed] [Cross Ref]
454. Cooper J.M., Korlipara L.V., Hart P.E., Bradley J.L., Schapira A.H. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: Predictor of efficacy of vitamin E and coenzyme Q10 therapy. *Eur. J. Neurol.* 2008;15:1371–1379. doi: 10.1111/j.1468-1331.2008.02318.x. [PubMed] [Cross Ref]
455. Hart P.E., Lodi R., Rajagopalan B., Bradley J.L., Crilley J.G., Turner C., Blamire A.M., Manners D., Styles P., Schapira A.H., et al. Antioxidant treatment of patients with Friedreich ataxia: Four-year follow-up. *Arch. Neurol.* 2005;62:621–626. doi: 10.1001/archneur.62.4.621. [PubMed] [Cross Ref]
456. Barbiroli B., Frassinetti C., Martinelli P., Iotti S., Lodi R., Cortelli P., Montagna P. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. *Cell. Mol. Biol.* 1997;43:741–749. [PubMed]
457. Abe K., Matsuo Y., Kadekawa J., Inoue S., Yanagihara T. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): Evaluation by noninvasive tissue oximetry. *J. Neurol. Sci.* 1999;162:65–68. doi: 10.1016/S0022-510X(98)00296-2. [PubMed] [Cross Ref]
458. Hanisch F., Zierz S. Only transient increase of serum CoQ subset 10 during long-term CoQ10 therapy in mitochondrial ophthalmoplegia. *Eur. J. Med. Res.* 2003;8:485–491. [PubMed]
459. Glover E.I., Martin J., Maher A., Thornhill R.E., Moran G.R., Tarnopolsky M.A. A randomized trial of coenzyme Q10 in mitochondrial disorders. *Muscle Nerve*. 2010;42:739–748. doi: 10.1002/mus.21758. [PubMed] [Cross Ref]
460. Huntington Study Group A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. *Neurology*. 2001;57:397–404. [PubMed]
461. Huntington Study Group Pre2CARE Investigators. Hyson H.C., Kieburtz K., Shoulson I., McDermott M., Ravina B., de Bleeck E.A., Cudkowicz M.E., Ferrante R.J., Como P., et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. *Mov. Disord.* 2010;25:1924–1928. doi: 10.1002/mds.22408. [PubMed] [Cross Ref]
462. Spurney C.F., Rocha C.T., Henricson E., Florence J., Mayhew J., Gorni K., Pasquali L., Pestronk A., Martin G.R., Hu F., et al. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. *Muscle Nerve*. 2011;44:174–178. doi: 10.1002/mus.22047. [PMC free article] [PubMed] [Cross Ref]
463. Folkers K., Wolaniuk J., Simonsen R., Morishita M., Vadhanavikit S. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. *Proc. Natl. Acad. Sci. USA*. 1985;82:4513–4516. doi: 10.1073/pnas.82.13.4513. [PMC free article] [PubMed] [Cross Ref]
464. Folkers K., Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. *Biochim. Biophys. Acta*. 1995;1271:281–286. doi: 10.1016/0925-4439(95)00040-B. [PubMed] [Cross Ref]
465. Linnane A.W., Kopsidas G., Zhang C., Yarovaya N., Kovalenko S., Papakostopoulos P., Eastwood H., Graves S., Richardson M. Cellular redox activity of coenzyme Q10: Effect of CoQ10 supplementation on human skeletal muscle. *Free Radic. Res.* 2002;36:445–453. doi: 10.1080/10715760290021306. [PubMed] [Cross Ref]
466. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., et al. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the

- functional decline. *Arch. Neurol.* 2002;59:1541–1550. doi: 10.1001/archneur.59.10.1541. [PubMed] [Cross Ref]
467. Müller T., Büttner T., Gholipour A.F., Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. *Neurosci. Lett.* 2003;341:201–204. doi: 10.1016/S0304-3940(03)00185-X. [PubMed] [Cross Ref]
 468. Storch A., Jost W.H., Vieregge P., Spiegel J., Greulich W., Durner J., Müller T., Kupsch A., Henningsen H., Oertel W.H., et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. *Arch. Neurol.* 2007;64:938–944. doi: 10.1001/archneur.64.7.nct60005. [PubMed] [Cross Ref]
 469. Sanoobar M., Eghtesadi S., Azimi A., Khalili M., Jazayeri S., Reza Gohari M. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis. *Int. J. Neurosci.* 2013;123:776–782. doi: 10.3109/00207454.2013.801844. [PubMed] [Cross Ref]
 470. Sanoobar M., Eghtesadi S., Azimi A., Khalili M., Khodadadi B., Jazayeri S., Gohari M.R., Aryaeian N. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: A double blind, placebo, controlled randomized clinical trial. *Nutr. Neurosci.* 2014 doi: 10.1179/1476830513Y.0000000106. [PubMed] [Cross Ref]
 471. Cordero M.D., Cano-García F.J., Alcocer-Gómez E., de Miguel M., Sánchez-Alcázar J.A. Oxidative stress correlates with headache symptoms in fibromyalgia: Coenzyme Q10 effect on clinical improvement. *PLoS One.* 2012;7:e35677. doi: 10.1371/journal.pone.0035677. [PMC free article] [PubMed] [Cross Ref]
 472. Cordero M.D., Alcocer-Gómez E., de Miguel M., Culic O., Carrión A.M., Alvarez-Suarez J.M., Bullón P., Battino M., Fernández-Rodríguez A., Sánchez-Alcázar J.A. Can coenzyme q10 improve clinical and molecular parameters in fibromyalgia? *Antioxid. Redox Signal.* 2013;19:1356–1361. doi: 10.1089/ars.2013.5260. [PubMed] [Cross Ref]
 473. Miyamae T., Seki M., Naga T., Uchino S., Asazuma H., Yoshida T., Iizuka Y., Kikuchi M., Imagawa T., Natsumeda Y., et al. Increased oxidative stress and coenzyme Q10 deficiency in juvenile fibromyalgia: Amelioration of hypercholesterolemia and fatigue by ubiquinol-10 supplementation. *Redox Rep.* 2013;18:12–19. doi: 10.1179/1351000212Y.0000000036. [PubMed] [Cross Ref]
 474. Lister R.E. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. *J. Int. Med. Res.* 2002;30:195–199. doi: 10.1177/147323000203000213. [PubMed] [Cross Ref]
 475. Kaufmann P., Thompson J.L., Levy G., Buchsbaum R., Shefner J., Krivickas L.S., Katz J., Rollins Y., Barohn R.J., Jackson C.E., et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. *Ann. Neurol.* 2009;66:235–244. doi: 10.1002/ana.21743. [PMC free article] [PubMed] [Cross Ref]
 476. Rozen T.D., Oshinsky M.L., Gebeline C.A., Bradley K.C., Young W.B., Shechter A.L., Silberstein S.D. Open label trial of coenzyme Q10 as a migraine preventive. *Cephalalgia.* 2002;22:137–141. doi: 10.1046/j.1468-2982.2002.00335.x. [PubMed] [Cross Ref]
 477. Hershey A.D., Powers S.W., Vockell A.L., Lecates S.L., Ellinor P.L., Segers A., Burdine D., Manning P., Kabbouche M.A. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. *Headache.* 2007;47:73–80. doi: 10.1111/j.1526-4610.2007.00652.x. [PubMed] [Cross Ref]
 478. Slater S.K., Nelson T.D., Kabbouche M.A., LeCates S.L., Horn P., Segers A., Manning P., Powers S.W., Hershey A.D. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. *Cephalalgia.* 2011;31:897–905. doi: 10.1177/0333102411406755. [PubMed] [Cross Ref]
 479. Forester B.P., Zuo C.S., Ravichandran C., Harper D.G., Du F., Kim S., Cohen B.M., Renshaw P.F. Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. *J.*

- Geriatr. Psychiatry Neurol. 2012;25:43–50. doi: 10.1177/0891988712436688. [PMC free article] [PubMed] [Cross Ref]
480. Stamelou M., Reuss A., Pilatus U., Magerkurth J., Niklowitz P., Eggert K.M., Krisp A., Menke T., Schade-Brittinger C., Oertel W.H., et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo-controlled trial. *Mov. Disord.* 2008;23:942–949. doi: 10.1002/mds.22023. [PubMed] [Cross Ref]
 481. Watts G.F., Playford D.A., Croft K.D., Ward N.C., Mori T.A., Burke V. Coenzyme Q10 improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. *Diabetologia.* 2002;45:420–426. doi: 10.1007/s00125-001-0760-y. [PubMed] [Cross Ref]
 482. Hodgson J.M., Watts G.F., Playford D.A., Burke V., Croft K.D. Coenzyme Q10 improves blood pressure and glycaemic control: A controlled trial in subjects with type 2 diabetes. *Eur. J. Clin. Nutr.* 2002;56:1137–1142. doi: 10.1038/sj.ejcn.1601464. [PubMed] [Cross Ref]
 483. Playford D.A., Watts G.F., Croft K.D., Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. *Atherosclerosis.* 2003;168:169–179. doi: 10.1016/S0021-9150(02)00417-3. [PubMed] [Cross Ref]
 484. Chew G.T., Watts G.F., Davis T.M., Stuckey B.G., Beilin L.J., Thompson P.L., Burke V., Currie P.J. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. *Diabetes Care.* 2008;31:1502–1509. doi: 10.2337/dc08-0118. [PMC free article] [PubMed] [Cross Ref]
 485. Hamilton S.J., Chew G.T., Watts G.F. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. *Diabetes Care.* 2009;32:810–812. doi: 10.2337/dc08-1736. [PMC free article] [PubMed] [Cross Ref]
 486. Kolahdouz Mohammadi R., Hosseinzadeh-Attar M.J., Eshraghian M.R., Nakhjavani M., Khorami E., Esteghamati A. The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients. *Minerva Gastroenterol. Dietol.* 2013;59:231–236. [PubMed]
 487. Suzuki S., Hinokio Y., Ohtomo M., Hirai M., Hirai A., Chiba M., Kasuga S., Satoh Y., Akai H., Toyota T. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. *Diabetologia.* 1998;41:584–588. doi: 10.1007/s001250050950. [PubMed] [Cross Ref]
 488. Henriksen J.E., Andersen C.B., Hother-Nielsen O., Vaag A., Mortensen S.A., Beck-Nielsen H. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with type 1 diabetes mellitus. *Diabet. Med.* 1999;16:312–318. doi: 10.1046/j.1464-5491.1999.00064.x. [PubMed] [Cross Ref]
 489. Hertz N., Lister R.E. Improved survival in patients with end-stage cancer treated with coenzyme Q10 and other antioxidants: A pilot study. *J. Int. Med. Res.* 2009;37:1961–1971. doi: 10.1177/147323000903700634. [PubMed] [Cross Ref]
 490. Lockwood K., Moesgaard S., Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. *Biochem. Biophys. Res. Commun.* 1994;199:1504–1508. doi: 10.1006/bbrc.1994.1401. [PubMed] [Cross Ref]
 491. Premkumar V.G., Yuvaraj S., Sathish S., Shanthi P., Sachdanandam P. Anti-angiogenic potential of Coenzyme Q10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. *Vascul. Pharmacol.* 2008;48:191–201. doi: 10.1016/j.vph.2008.02.003. [PubMed] [Cross Ref]
 492. Lesser G.J., Case D., Stark N., Williford S., Giguere J., Garino L.A., Naughton M.J., Vitolins M.Z., Lively M.O., Shaw E.G., et al. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. *J. Support Oncol.* 2013;11:31–42. [PMC free article] [PubMed]
 493. Hoenjet K.M., Dagnelie P.C., Delaere K.P., Wijckmans N.E., Zambon J.V., Oosterhof G.O. Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: A randomised placebo-controlled

- study. *Eur. Urol.* 2005;47:433–439. doi: 10.1016/j.eururo.2004.11.017. [PubMed] [Cross Ref]
494. Rusciani L., Proietti I., Paradisi A., Rusciani A., Guerriero G., Mammone A., de Gaetano A., Lippa S. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: A 3-year trial with recombinant interferon-alpha and 5-year follow-up. *Melanoma Res.* 2007;17:177–183. doi: 10.1097/CMR.0b013e32818867a0. [PubMed] [Cross Ref]
495. Gazdík K., Gvozdjaková A., Kucharská J., Spustová V., Braunová Z., Džurík R. Effect of coenzyme Q10 in patients with kidney diseases. *Cas. Lek. Cesk.* 2001;140:307–310. [PubMed]
496. Sakata T., Furuya R., Shimazu T., Odamaki M., Ohkawa S., Kumagai H. Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. *Blood Purif.* 2008;26:371–378. doi: 10.1159/000135605. [PubMed] [Cross Ref]
497. Mori T.A., Burke V., Puddey I., Irish A., Cowpland C.A., Beilin L., Dogra G., Watts G.F. The effects of omega-3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: A randomized controlled trial. *J. Hypertens.* 2009;27:1863–1872. doi: 10.1097/HJH.0b013e32832e1bd9. [PubMed] [Cross Ref]
498. Shojaei M., Djalali M., Khatami M., Siassi F., Eshraghian M. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy. *Iran J. Kidney Dis.* 2011;5:114–118. [PubMed]
499. Kaikkonen J., Nyssönen K., Tomasi A., Iannone A., Tuomainen T.P., Porkkala-Sarataho E., Salonen J.T. Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: A randomized placebo-controlled clinical study. *Free Radic. Res.* 2000;33:329–340. doi: 10.1080/10715760000301501. [PubMed] [Cross Ref]
500. Lee Y.J., Cho W.J., Kim J.K., Lee D.C. Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: A double-blind randomized controlled study. *J. Med. Food.* 2011;14:386–390. doi: 10.1089/jmf.2010.1202. [PubMed] [Cross Ref]
501. Young J.M., Florkowski C.M., Molyneux S.L., McEwan R.G., Frampton C.M., Nicholls M.G., Scott R.S., George P.M. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. *Am. J. Hypertens.* 2012;25:261–270. doi: 10.1038/ajh.2011.209. [PubMed] [Cross Ref]
502. Mabuchi H., Nohara A., Kobayashi J., Kawashiri M.A., Katsuda S., Inazu A., Koizumi J., Hokuriku Lipid Research Group Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study. *Atherosclerosis.* 2007;195:e182–e189. doi: 10.1016/j.atherosclerosis.2007.06.010. [PubMed] [Cross Ref]
503. Young J.M., Florkowski C.M., Molyneux S.L., McEwan R.G., Frampton C.M., George P.M., Scott R.S. Effect of coenzyme Q10 supplementation on simvastatin-induced myalgia. *Am. J. Cardiol.* 2007;100:1400–1403. doi: 10.1016/j.amjcard.2007.06.030. [PubMed] [Cross Ref]
504. Bookstaver D.A., Burkhalter N.A., Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. *Am. J. Cardiol.* 2012;110:526–529. doi: 10.1016/j.amjcard.2012.04.026. [PubMed] [Cross Ref]
505. Zlatohlavek L., Vrablik M., Grauova B., Motykova E., Ceska R. The effect of coenzyme Q10 in statin myopathy. *Neuro Endocrinol. Lett.* 2012;33:98–101. [PubMed]
506. Fedacko J., Pella D., Fedackova P., Hänninen O., Tuomainen P., Jarcuska P., Lopuchovsky T., Jedlickova L., Merkovska L., Littarru G.P. Coenzyme Q10 and selenium in statin-associated myopathy treatment. *Can. J. Physiol. Pharmacol.* 2013;91:165–170. doi: 10.1139/cjpp-2012-0118. [PubMed] [Cross Ref]
507. Gvozdjaková A., Kucharská J., Bartkovjaková M., Gazdík K., Gazdík F.E. Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma. *Biofactors.* 2005;25:235–240. doi: 10.1002/biof.5520250129. [PubMed] [Cross Ref]
508. Teran E., Hernandez I., Nieto B., Tavera R., Ocampo J.E., Calle A. Coenzyme Q10 supplementation

- during pregnancy reduces the risk of pre-eclampsia. *Int. J. Gynaecol. Obstet.* 2009;105:43–45. doi: 10.1016/j.ijgo.2008.11.033. [PubMed] [Cross Ref]
509. De Luca C., Kharaeva Z., Raskovic D., Pastore P., Luci A., Korkina L. Coenzyme Q10, vitamin E, selenium, and methionine in the treatment of chronic recurrent viral mucocutaneous infections. *Nutrition.* 2012;28:509–514. doi: 10.1016/j.nut.2011.08.003. [PubMed] [Cross Ref]
 510. Kharaeva Z., Gostova E., de Luca C., Raskovic D., Korkina L. Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients. *Nutrition.* 2009;25:295–302. doi: 10.1016/j.nut.2008.08.015. [PubMed] [Cross Ref]
 511. Fogagnolo P., Sacchi M., Ceresara G., Paderni R., Lapadula P., Orzalesi N., Rossetti L. The effects of topical coenzyme Q10 and vitamin E d- α -tocopheryl polyethylene glycol 1000 succinate after cataract surgery: A clinical and in vivo confocal study. *Ophthalmologica.* 2013;229:26–31. doi: 10.1159/000342196. [PubMed] [Cross Ref]
 512. Safarinejad M.R., Safarinejad S., Shafiei N., Safarinejad S. Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: A double-blind, placebo controlled, randomized study. *J. Urol.* 2012;188:526–531. doi: 10.1016/j.juro.2012.03.131. [PubMed] [Cross Ref]
 513. Gilbert E.F. Carnitine deficiency. *Pathology.* 1985;17:161–171. doi: 10.3109/00313028509063752. [PubMed] [Cross Ref]
 514. Siliprandi N., Siliprandi D., Ciman M. Stimulation of oxidation of mitochondrial fatty acids and of acetate by acetylcarnitine. *Biochem. J.* 1965;96:777–780. [PMC free article] [PubMed]
 515. Liu J., Head E., Kuratsune H., Cotman C.W., Ames B.N. Comparison of the effects of l-carnitine and acetyl-l-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. *Ann. N. Y. Acad. Sci.* 2004;1033:117–131. doi: 10.1196/annals.1320.011. [PubMed] [Cross Ref]
 516. Musicco C., Capelli V., Pesce V., Timperio A.M., Calvani M., Mosconi L., Cantatore P., Gadaleta M.N. Rat liver mitochondrial proteome: Changes associated with aging and acetyl-l-carnitine treatment. *J. Proteomics.* 2011;74:2536–2547. doi: 10.1016/j.jpro.2011.05.041. [PubMed] [Cross Ref]
 517. Pesce V., Nicassio L., Fracasso F., Musicco C., Cantatore P., Gadaleta M.N. Acetyl-l-carnitine activates the peroxisome proliferator-activated receptor- γ coactivators PGC-1 α /PGC-1 β -dependent signaling cascade of mitochondrial biogenesis and decreases the oxidized peroxiredoxins content in old rat liver. *Rejuvenation Res.* 2012;15:136–139. doi: 10.1089/rej.2011.1255. [PubMed] [Cross Ref]
 518. Bertoli M., Battistella P.A., Vergani L., Naso A., Gasparotto M.L., Romagnoli G.F., Angelini C. Carnitine deficiency induced during hemodialysis and hyperlipidemia: Effect of replacement therapy. *Am. J. Clin. Nutr.* 1981;34:1496–1500. [PubMed]
 519. Kletzmayer J., Mayer G., Legenstein E., Heinz-Peer G., Leitha T., Hörl W.H., Kovarik J. Anemia and carnitine supplementation in hemodialyzed patients. *Kidney Int. Suppl.* 1999;69:S93–S106. doi: 10.1038/sj.ki.4490857. [PubMed] [Cross Ref]
 520. Thomas S., Fischer F.P., Mettang T., Pauli-Magnus C., Weber J., Kuhlmann U. Effects of l-carnitine on leukocyte function and viability in hemodialysis patients: A double-blind randomized trial. *Am. J. Kidney Dis.* 1999;34:678–687. doi: 10.1016/S0272-6386(99)70393-8. [PubMed] [Cross Ref]
 521. Chazot C., Blanc C., Huot J.M., Charra B., Jean G., Laurent G. Nutritional effects of carnitine supplementation in hemodialysis patients. *Clin. Nephrol.* 2003;59:24–30. doi: 10.5414/CNP59024. [PubMed] [Cross Ref]
 522. Vaux E.C., Taylor D.J., Altmann P., Rajagopalan B., Graham K., Cooper R., Bonomo Y., Styles P. Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. *Nephron Clin. Pract.* 2004;97:c41–c48. doi: 10.1159/000078399. [PubMed] [Cross Ref]
 523. Steiber A.L., Davis A.T., Spry L., Strong J., Buss M.L., Ratkiewicz M.M., Weatherspoon L.J. Carnitine treatment improved quality-of-life measure in a sample of Midwestern hemodialysis patients. *J.*

- Parenter. Enteral. Nutr. 2006;30:10–15. doi: 10.1177/014860710603000110. [PubMed] [Cross Ref]
524. Signorelli S.S., Fatuzzo P., Rapisarda F., Neri S., Ferrante M., Oliveri Conti G., Fallico R., di Pino L., Pennisi G., Celotta G., et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis. *Drugs Aging*. 2006;23:263–270. doi: 10.2165/00002512-200623030-00008. [PubMed] [Cross Ref]
525. Rathod R., Baig M.S., Khandelwal P.N., Kulkarni S.G., Gade P.R., Siddiqui S. Results of a single blind, randomized, placebo-controlled clinical trial to study the effect of intravenous L-carnitine supplementation on health-related quality of life in Indian patients on maintenance hemodialysis. *Indian J. Med. Sci*. 2006;60:143–153. doi: 10.4103/0019-5359.24678. [PubMed] [Cross Ref]
526. Duranay M., Akay H., Yilmaz F.M., Senes M., Tekeli N., Yücel D. Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. *Nephrol. Dial. Transplant*. 2006;21:3211–3214. doi: 10.1093/ndt/gfl356. [PubMed] [Cross Ref]
527. Verrina E., Caruso U., Calevo M.G., Emma F., Sorino P., de Palo T., Lavoratti G., Turrini Dertenno L., Cassanello M., Cerone R., et al. Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis. *Pediatr. Nephrol*. 2007;22:727–733. doi: 10.1007/s00467-006-0408-8. [PubMed] [Cross Ref]
528. Fatouros I.G., Douroudos I., Panagoutsos S., Pasadakis P., Nikolaidis M.G., Chatzinikolaou A., Sovatzidis A., Michailidis Y., Jamurtas A.Z., Mandalidis D., et al. Effects of L-carnitine on oxidative stress responses in patients with renal disease. *Med. Sci. Sports Exerc*. 2010;42:1809–1818. doi: 10.1249/MSS.0b013e3181dbacab. [PubMed] [Cross Ref]
529. Hakeshzadeh F., Tabibi H., Ahmadinejad M., Malakoutian T., Hedayati M. Effects of L-carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients. *Renal Failure*. 2010;32:1109–1114. doi: 10.3109/0886022X.2010.510617. [PubMed] [Cross Ref]
530. Tabibi H., Hakeshzadeh F., Hedayati M., Malakoutian T. Effects of L-carnitine supplement on serum amyloid A and vascular inflammation markers in hemodialysis patients: A randomized controlled trial. *J. Ren. Nutr*. 2011;21:485–491. doi: 10.1053/j.jrn.2011.01.001. [PubMed] [Cross Ref]
531. Suchitra M.M., Ashalatha V.L., Sailaja E., Rao A.M., Reddy V.S., Bitla A.R., Sivakumar V., Rao P.V. The effect of L-carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients. *Saudi J. Kidney Dis. Transpl*. 2011;22:1155–1159. [PubMed]
532. Naini A.E., Sadeghi M., Mortazavi M., Moghadas M., Harandi A.A. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. *Saudi J. Kidney Dis. Transpl*. 2012;23:484–488. [PubMed]
533. Sgambat K., Frank L., Ellini A., Sable C., Moudgil A. Carnitine supplementation improves cardiac strain rate in children on chronic hemodialysis. *Pediatr. Nephrol*. 2012;27:1381–1387. doi: 10.1007/s00467-012-2144-6. [PubMed] [Cross Ref]
534. Mercadal L., Coudert M., Vassault A., Pieroni L., Debure A., Ouziala M., Depreneuf H., Fumeron C., Servais A., Bassilios N., et al. L-Carnitine treatment in incident hemodialysis patients: The multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. *Clin. J. Am. Soc. Nephrol*. 2012;7:1836–1842. doi: 10.2215/CJN.12431211. [PMC free article] [PubMed] [Cross Ref]
535. Mingrone G., Greco A.V., Capristo E., Benedetti G., Giancaterini A., de Gaetano A., Gasbarrini G. L-Carnitine improves glucose disposal in type 2 diabetic patients. *J. Am. Coll. Nutr*. 1999;18:77–82. doi: 10.1080/07315724.1999.10718830. [PubMed] [Cross Ref]
536. Giancaterini A., de Gaetano A., Mingrone G., Gniuli D., Liverani E., Capristo E., Greco A.V. Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients. *Metabolism*. 2000;49:704–708. doi: 10.1053/meta.2000.6250. [PubMed] [Cross Ref]
537. De Grandis D., Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. *Drugs R&D*. 2002;3:223–231. doi: 10.2165/00126839-200203040-00001. [PubMed] [Cross Ref]

538. Derosa G., Cicero A.F., Gaddi A., Mugellini A., Ciccarelli L., Fogari R. The effect of l-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. *Clin. Ther.* 2003;25:1429–1439. doi: 10.1016/S0149-2918(03)80130-3. [PubMed] [Cross Ref]
539. Ragozzino G., Mattera E., Madrid E., Salomone P., Fasano C., Gioia F., Acerra G., del Guercio R., Federico P. Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: Results of a pilot trial. *Drugs R&D.* 2004;5:185–190. doi: 10.2165/00126839-200405040-00001. [PubMed] [Cross Ref]
540. Sima A.A., Calvani M., Mehra M., Amato A. Acetyl-L-Carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: An analysis of two randomized placebo-controlled trials. *Diabetes Care.* 2005;28:89–94. doi: 10.2337/diacare.28.1.89. [PubMed] [Cross Ref]
541. Rahbar A.R., Shakerhosseini R., Saadat N., Taleban F., Pordal A., Gollestan B. Effect of l-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus. *Eur. J. Clin. Nutr.* 2005;59:592–596. doi: 10.1038/sj.ejcn.1602109. [PubMed] [Cross Ref]
542. Solfrizzi V., Capurso C., Colacicco A.M., D’Introno A., Fontana C., Capurso S.A., Torres F., Gadaleta A.M., Koverech A., Capurso A., et al. Efficacy and tolerability of combined treatment with l-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. *Atherosclerosis.* 2006;188:455–461. doi: 10.1016/j.atherosclerosis.2005.11.024. [PubMed] [Cross Ref]
543. Signorelli S.S., Neri S., di Pino L., Marchese G., Ferrante M., Oliveri Conti G., Fallico R., Celotta G., Pennisi G., Anzaldi M. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. *Diabetes Res. Clin. Pract.* 2006;72:231–237. doi: 10.1016/j.diabres.2005.10.007. [PubMed] [Cross Ref]
544. Malaguarnera M., Vacante M., Avitabile T., Malaguarnera M., Cammalleri L., Motta M. l-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. *Am. J. Clin. Nutr.* 2009;89:71–76. doi: 10.3945/ajcn.2008.26251. [PubMed] [Cross Ref]
545. Ruggenenti P., Cattaneo D., Loriga G., Ledda F., Motterlini N., Gherardi G., Orisio S., Remuzzi G. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: Effects of acetyl-l-carnitine therapy. *Hypertension.* 2009;54:567–574. doi: 10.1161/HYPERTENSIONAHA.109.132522. [PubMed] [Cross Ref]
546. Molino A., Cascino A., Conte C., Ramaccini C., Rossi Fanelli F., Laviano A. Caloric restriction and l-carnitine administration improves insulin sensitivity in patients with impaired glucose metabolism. *J. Parenter. Enteral. Nutr.* 2010;34:295–299. doi: 10.1177/0148607109353440. [PubMed] [Cross Ref]
547. Uzun N., Sarikaya S., Uluduz D., Aydin A. Peripheral and autonomic neuropathy in children with type 1 diabetes mellitus: The effect of l-carnitine treatment on the peripheral and autonomic nervous system. *Electromyogr. Clin. Neurophysiol.* 2005;45:343–351. [PubMed]
548. Loffredo L., Pignatelli P., Cangemi R., Andreozzi P., Panico M.A., Meloni V., Violi F. Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: Effect of an antioxidant treatment. *J. Vasc. Surg.* 2006;44:525–530. doi: 10.1016/j.jvs.2006.05.023. [PubMed] [Cross Ref]
549. De Marchi S., Zecchetto S., Rigoni A., Prior M., Fondrieschi L., Scuro A., Rulfo F., Arosio E. Propionyl-l-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia. *Cardiovasc. Drugs Ther.* 2012;26:401–408. doi: 10.1007/s10557-012-6408-y. [PubMed] [Cross Ref]
550. Goldenberg N.A., Krantz M.J., Hiatt W.R. l-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: A multicenter, randomized, double-blind, placebo-controlled trial. *Vasc. Med.* 2012;17:145–154. doi: 10.1177/1358863X12442264. [PubMed] [Cross Ref]

551. Xu X.Q., Jing Z.C., Jiang X., Zhao Q.H., He J., Dai L.Z., Wu W.H., Li Y., Yao J. Clinical efficacy of intravenous l-carnitine in patients with right-sided heart failure induced by pulmonary arterial hypertension. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2010;38:152–155. [PubMed]
552. Serati A.R., Motamedi M.R., Emami S., Varedi P., Movahed M.R. l-Carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. *Cardiology*. 2010;116:178–182. doi: 10.1159/000318810. [PubMed] [Cross Ref]
553. Lango R., Smoleński R.T., Rogowski J., Siebert J., Wujtewicz M., Słomińska E.M., Lysiak-Szydłowska W., Yacoub M.H. Propionyl-l-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. *Cardiovasc. Drugs Ther.* 2005;19:267–275. doi: 10.1007/s10557-005-3349-8. [PubMed] [Cross Ref]
554. Xiang D., Sun Z., Xia J., Dong N., Du X., Chen X. Effect of l-carnitine on cardiomyocyte apoptosis and cardiac function in patients undergoing heart valve replacement operation. *J. Huazhong Univ. Sci. Technol. Med. Sci.* 2005;25:501–504. doi: 10.1007/BF02895999. [PubMed] [Cross Ref]
555. Łapiński T.W., Grzeszczuk A. The impact of carnitine on serum ammonia concentration and lipid metabolism in patients with alcoholic liver cirrhosis. *Pol. Merkur. Lekarski*. 2003;15:38–41. [PubMed]
556. Lim C.Y., Jun D.W., Jang S.S., Cho W.K., Chae J.D., Jun J.H. Effects of carnitine on peripheral blood mitochondrial DNA copy number and liver function in non-alcoholic fatty liver disease. *Korean J. Gastroenterol.* 2010;55:384–389. doi: 10.4166/kjg.2010.55.6.384. [PubMed] [Cross Ref]
557. Malaguarnera M., Pistone G., Astuto M., dell'Arte S., Finocchiaro G., lo Giudice E., Pennisi G. l-Carnitine in the treatment of mild or moderate hepatic encephalopathy. *Dig. Dis.* 2003;21:271–275. doi: 10.1159/000073347. [PubMed] [Cross Ref]
558. Malaguarnera M., Vacante M., Giordano M., Motta M., Bertino G., Pennisi M., Neri S., Malaguarnera M., Li Volti G., Galvano F. l-Carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon- α 2b plus ribavirin. *World J. Gastroenterol.* 2011;17:4414–4420. doi: 10.3748/wjg.v17.i39.4414. [PMC free article] [PubMed] [Cross Ref]
559. 245. Neri S., Pistone G., Saraceno B., Pennisi G., Luca S., Malaguarnera M. l-Carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. *Neuropsychobiology*. 2003;47:94–97. doi: 10.1159/000070016. [PubMed] [Cross Ref]
560. Malaguarnera M., Vacante M., Giordano M., Pennisi G., Bella R., Rampello L., Malaguarnera M., Li Volti G., Galvano F. Oral acetyl-l-carnitine therapy reduces fatigue in overt hepatic encephalopathy: A randomized, double-blind, placebo-controlled study. *Am. J. Clin. Nutr.* 2011;93:799–808. doi: 10.3945/ajcn.110.007393. [PubMed] [Cross Ref]
561. Tomassini V., Pozzilli C., Onesti E., Pasqualetti P., Marinelli F., Pisani A., Fieschi C. Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomised, double-blind, crossover trial. *J. Neurol. Sci.* 2004;218:103–108. doi: 10.1016/j.jns.2003.11.005. [PubMed] [Cross Ref]
562. Gavrilova S.I., Kalyn IaB., Kolykhalov I.V., Roshchina I.F., Selezneva N.D. Acetyl-l-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia. *Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova*. 2011;111:16–22. [PubMed]
563. Tarighat Esfanjani A., Mahdavi R., Ebrahimi Mameghani M., Talebi M., Nikniaz Z., Safaiyan A. The effects of magnesium, l-carnitine, and concurrent magnesium-l-carnitine supplementation in migraine prophylaxis. *Biol. Trace Elem. Res.* 2012;150:42–48. doi: 10.1007/s12011-012-9487-5. [PubMed] [Cross Ref]
564. Pistone G., Marino A., Leotta C., dell'Arte S., Finocchiaro G., Malaguarnera M. Levocarnitine administration in elderly subjects with rapid muscle fatigue: Effect on body composition, lipid

- profile and fatigue. *Drugs Aging*. 2003;20:761–767. doi: 10.2165/00002512-200320100-00004. [PubMed] [Cross Ref]
565. Miyagawa T., Kawamura H., Obuchi M., Ikesaki A., Ozaki A., Tokunaga K., Inoue Y., Honda M. Effects of oral l-carnitine administration in narcolepsy patients: A randomized, double-blind, cross-over and placebo-controlled trial. *PLoS One*. 2013;8:e53707. doi: 10.1371/journal.pone.0053707. [PMC free article] [PubMed] [Cross Ref]
 566. Rossini M., di Munno O., Valentini G., Bianchi G., Biasi G., Cacace E., Malesci D., la Montagna G., Viapiana O., Adami S. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. *Clin. Exp. Rheumatol*. 2007;25:182–188. [PubMed]
 567. Vermeulen R.C., Scholte H.R. Exploratory open label, randomized study of acetyl- and propionyl-carnitine in chronic fatigue syndrome. *Psychosom. Med*. 2004;66:276–282. doi: 10.1097/01.psy.0000116249.60477.e9. [PubMed] [Cross Ref]
 568. Beghi E., Pupillo E., Bonito V., Buzzi P., Caponnetto C., Chiò A., Corbo M., Giannini F., Inghilleri M., Bella V.L., et al. Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for ALS. *Amyotroph. Lateral Scler. Frontotemporal Degener*. 2013;14:397–405. doi: 10.3109/21678421.2013.764568. [PubMed] [Cross Ref]
 569. Cruciani R.A., Dvorkin E., Homel P., Malamud S., Culliney B., Lapin J., Portenoy R.K., Esteban-Cruciani N. Safety, tolerability and symptom outcomes associated with l-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: A phase I/II study. *J. Pain Symptom Manag*. 2006;32:551–559. doi: 10.1016/j.jpainsymman.2006.09.001. [PubMed] [Cross Ref]
 570. Cruciani R.A., Dvorkin E., Homel P., Culliney B., Malamud S., Lapin J., Portenoy R.K., Esteban-Cruciani N. l-Carnitine supplementation in patients with advanced cancer and carnitine deficiency: A double-blind, placebo-controlled study. *J. Pain Symptom Manag*. 2009;37:622–631. doi: 10.1016/j.jpainsymman.2008.03.021. [PubMed] [Cross Ref]
 571. Cruciani R.A., Zhang J.J., Manola J., Cella D., Ansari B., Fisch M.J. l-Carnitine supplementation for the management of fatigue in patients with cancer: An eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. *J. Clin. Oncol*. 2012;30:3864–3869. doi: 10.1200/JCO.2011.40.2180. [PMC free article] [PubMed] [Cross Ref]
 572. Mantovani G. Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. *Eur. Rev. Med. Pharmacol. Sci*. 2010;14:292–301. [PubMed]
 573. Madeddu C., Dessì M., Panzone F., Serpe R., Antoni G., Cau M.C., Montaldo L., Mela Q., Mura M., Astara G., et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. *Clin. Nutr*. 2012;31:176–182. doi: 10.1016/j.clnu.2011.10.005. [PubMed] [Cross Ref]
 574. Kraft M., Kraft K., Gärtner S., Mayerle J., Simon P., Weber E., Schütte K., Stieler J., Koula-Jenik H., Holzhauer P., et al. l-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) a randomized multicentre trial. *Nutr. J*. 2012;11:52. doi: 10.1186/1475-2891-11-52. [PMC free article] [PubMed] [Cross Ref]
 575. Hershman D.L., Unger J.M., Crew K.D., Minasian L.M., Awad D., Moinpour C.M., Hansen L., Lew D.L., Greenlee H., Fehrenbacher L., et al. Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. *J. Clin. Oncol*. 2013;31:2627–2633. doi: 10.1200/JCO.2012.44.8738. [PMC free article] [PubMed] [Cross Ref]
 576. Schöls L., Zange J., Abele M., Schillings M., Skipka G., Kuntz-Hehner S., van Beekvelt M.C., Collier W.N., Müller K., Klockgether T., et al. l-Carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. *J. Neural Transm*. 2005;112:789–796. doi: 10.1007/s00702-004-0216-x. [PubMed] [Cross Ref]
 577. El-Beshlawy A., Ragab L., Fattah A.A., Ibrahim I.Y., Hamdy M., Makhlouf A., Aoun E., Hoffbrand V., Taher A. Improvement of cardiac function in thalassemia major treated with l-carnitine. *Acta*

- Haematol. 2004;111:143–148. doi: 10.1159/000076522. [PubMed] [Cross Ref]
578. Karimi M., Mohammadi F., Behmanesh F., Samani S.M., Borzouee M., Amoozgar H., Haghpahan S. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. *Eur. J. Haematol.* 2010;84:52–58. doi: 10.1111/j.1600-0609.2009.01356.x. [PubMed] [Cross Ref]
579. Ellaway C.J., Peat J., Williams K., Leonard H., Christodoulou J. Medium-term open label trial of l-carnitine in Rett syndrome. *Brain Dev.* 2001;23:S85–S89. doi: 10.1016/S0387-7604(01)00346-1. [PubMed] [Cross Ref]
580. Torrioli M.G., Vernacotola S., Peruzzi L., Tabolacci E., Mila M., Militeri R., Musumeci S., Ramos F.J., Frontera M., Sorge G., et al. A double-blind, parallel, multicenter comparison of l-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. *Am. J. Med. Genet. A.* 2008;146:803–812. doi: 10.1002/ajmg.a.32268. [PubMed] [Cross Ref]
581. Geier D.A., Kern J.K., Davis G., King P.G., Adams J.B., Young J.L., Geier M.R. A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. *Med. Sci. Monit.* 2011;17:PI15–PI23. doi: 10.12659/MSM.881792. [PMC free article] [PubMed] [Cross Ref]
582. Osio M., Muscia F., Zampini L., Nascimbene C., Mailland E., Cargnel A., Mariani C. Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: An open label study. *J. Peripher. Nerv. Syst.* 2006;11:72–76. doi: 10.1111/j.1085-9489.2006.00066.x. [PubMed] [Cross Ref]
583. Youle M., Osio M., ALCAR Study Group A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl l-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. *HIV Med.* 2007;8:241–250. doi: 10.1111/j.1468-1293.2007.00467.x. [PubMed] [Cross Ref]
584. Benedini S., Perseghin G., Terruzzi I., Scifo P., Invernizzi P.L., del Maschio A., Lazzarin A., Luzi L. Effect of l-acetylcarnitine on body composition in HIV-related lipodystrophy. *Horm. Metab. Res.* 2009;41:840–845. doi: 10.1055/s-0029-1225625. [PubMed] [Cross Ref]
585. Pignatelli P., Tellan G., Marandola M., Carnevale R., Loffredo L., Schillizzi M., Proietti M., Violi F., Chirletti P., Delogu G. Effect of l-carnitine on oxidative stress and platelet activation after major surgery. *Acta Anaesthesiol. Scand.* 2011;55:1022–1028. [PubMed]
586. Mikhailova T.L., Sishkova E., Poniewierka E., Zhidkov K.P., Bakulin I.G., Kupcinkas L., Lesniakowski K., Grinevich V.B., Malecka-Panas E., Ardizzone S., et al. Randomised clinical trial: The efficacy and safety of propionyl-l-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. *Aliment. Pharmacol. Ther.* 2011;34:1088–1097. doi: 10.1111/j.1365-2036.2011.04844.x. [PubMed] [Cross Ref]
587. Mattiazzi M., Vijayvergiya C., Gajewski C.D., deVivo D.C., Lenaz G., Wiedmann M., Manfredi G. The mtDNA T8993G (NARP) mutation results in an impairment of oxidative phosphorylation that can be improved by antioxidants. *Hum. Mol. Genet.* 2004;13:869–879. doi: 10.1093/hmg/ddh103. [PubMed] [Cross Ref]
588. Chinnery P.F. Mitochondrial Disorders Overview. Synonyms: Mitochondrial Encephalomyopathies, Mitochondrial Myopathies, Oxidative Phosphorylation Disorders, Respiratory Chain Disorders. [(accessed on 3 November 2014)]; Available online: <http://www.ncbi.nlm.nih.gov/books/NBK1224>.
589. Di Mauro S., Mancuso M. Mitochondrial diseases: Therapeutic approaches. *Biosci. Rep.* 2007;27:125–137. doi: 10.1007/s10540-007-9041-4. [PubMed] [Cross Ref]
590. Smith R.A., Murphey M.P. Mitochondria-targeted antioxidants as therapies. *Discov. Med.* 2011;11:106–114. [PubMed]
591. Lee S.H., Kim M.J., Kim B.J., Kim S.R., Chun S., Ryu J.S., Kim G.S., Lee M.C., Koh J.M., Chung S.J. Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease. *Mov. Disord.* 2010;25:332–340. doi: 10.1002/mds.22866. [PubMed] [Cross Ref]
592. Pagano G., Aiello Talamanca A., Castello G., d'Ischia M., Pallardó F.V., Petrović S., Porto B., Tiano L.,

- Zatterale A. From clinical description to in vitro and animal studies, and backwards to patients: Oxidative stress and mitochondrial dysfunction in Fanconi anaemia. *Free Radic. Biol. Med.* 2013;58:118–125. doi: 10.1016/j.freeradbiomed.2013.01.015. [PubMed] [Cross Ref]
593. Seco-Cervera M., Spis M., García-Giménez J.L. Oxidative stress and antioxidant response in fibroblasts from Werner and Atypical Werner Syndromes. *Aging.* 2014;6:231–245. [PMC free article] [PubMed]
594. Bhagavan H.N., Chopra R.K. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. *Mitochondrion.* 2007;7:S78–S88. doi: 10.1016/j.mito.2007.03.003. [PubMed] [Cross Ref]
595. Roginsky V.A., Tashlitsky V.N., Skulachev V.P. Chain-breaking antioxidant activity of reduced forms of mitochondria-targeted quinones, a novel type of geroprotectors. *Aging.* 2009;1:481–489. [PMC free article] [PubMed]
596. Teichert J., Hermann R., Ruus P., Preiss R. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. *J. Clin. Pharmacol.* 2003;43:1257–1267. doi: 10.1177/0091270003258654. [PubMed] [Cross Ref]
597. Pettegrew J.W., Levine J., McClure R.J. Acetyl-L-carnitine physical-chemical, metabolic and therapeutic properties: Relevance for its mode of action in Alzheimer's disease and geriatric depression. *Mol. Psychiatry.* 2000;5:616–632. doi: 10.1038/sj.mp.4000805. [PubMed] [Cross Ref]
598. Madiraju P., Pande S.V., Prentki M., Murthy Madiraju S.R. Mitochondrial acetylcarnitine provides acetyl groups for nuclear histone acetylation. *Epigenetics.* 2009;4:4–6. doi: 10.4161/epi.4.6.9767. [PubMed] [Cross Ref]
599. Rosca M.G., Lemieux H., Hoppel C.L. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? *Adv. Drug Deliv. Rev.* 2009;61:1332–1342. [PMC free article] [PubMed]
600. Breithaupt-Grögler K., Niebch G., Schneider E., Erb K., Hermann R., Blume H.H., Schug B.S., Belz G.G. Dose-proportionality of oral thioctic acid—Coincidence of assessments via pooled plasma and individual data. *Eur. J. Pharm. Sci.* 1999;8:57–65. doi: 10.1016/S0928-0987(98)00061-X. [PubMed] [Cross Ref]
601. Rebouche C.J. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. *Ann. N. Y. Acad. Sci.* 2004;1033:30–41. doi: 10.1196/annals.1320.003. [PubMed] [Cross Ref]
602. Camp K.M., Lloyd-Puryear M.A., Yao L., Groft S.C., Parisi M.A., Mulberg A., Gopal-Srivastava R., Cederbaum S., Enns G.M., Ershow A.G., et al. Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism. *Mol. Genet. Metab.* 2013;109:319–328. doi: 10.1016/j.ymgme.2013.05.008. [PMC free article] [PubMed] [Cross Ref]
603. Naci H, Brugts JJ, Fleurence R, et al. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. *Eur J Prev Cardiol.* 2013;20(4):641–57. [PubMed]
604. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev.* 2013;1:CD00481. [PubMed]
605. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. *Cardiovasc Drugs Ther.* 2005;19(6):403–14. [PubMed]
606. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. *JAMA.* 2002;288:462–67. [PubMed]
607. Pasternak RC, Smith SC, Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. *Stroke.* 2002;33:2337–41. [PubMed]
608. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. *Am J Cardiol.* 2007;100:1400–3. [PubMed]
609. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.

- Curr Opin Lipidol. 2007;18:401–8. [PubMed]
610. Wyman M, Leonard M, Morledge T. Coenzyme Q10: a therapy for hypertension and statin-induced myalgia? *Cleve Clin J Med*. 2010;77:435–42. [PubMed]
 611. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. *J Am Coll Cardiol*. 2007;49:2231–37. [PubMed]
 612. Potgieter M, Pretorius E, Pepper MS. Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation. *Nutr Rev*. 2013;71:180–88. [PubMed]
 613. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. *Am J Cardiol*. 2007;99:1409–12. [PubMed]
 614. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. *Am J Cardiol*. 2012;110:526–29. [PubMed]
 615. Fedacko J, Pella D, Fedackova P, et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. *Can J Physiol Pharmacol*. 2013;91:165–70. [PubMed]
 616. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. *Can J Cardiol*. 2013;29:1553–68. [PubMed]
 617. Tamaki N, Ueno H, Morinaga Y, Shiiya T, Nakazato M. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. *J Atheroscler Thromb*. 2012;19:532–538. doi: 10.5551/jat.10835. [PubMed] [Cross Ref]
 618. Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A. Worldwide risk factors for heart failure: A systematic review and pooled analysis. *Int J Cardiol*. 2013;168:1186–1194. doi: 10.1016/j.ijcard.2012.11.065. [PMC free article] [PubMed] [Cross Ref]
 619. Gutiérrez J, Rivera J, Shamah T, Villalpando S, Cuevas L, Romero M, Hernández M. Encuesta Nacional de Salud y Nutrición. México: Resultados nacionales. Cuernavaca, México. Instituto Nacional de Salud Pública; 2012.
 620. Gómez E, Gisbert J, Moreno J, García L, Moreno R. A pilot study of atorvastatin treatment in dyslipemic non-alcoholic fatty liver patients. *Aliment Pharmacol Ther*. 2006;23:1643–1647. doi: 10.1111/j.1365-2036.2006.02926.x. [PubMed] [Cross Ref]
 621. Catapano AL, Reiner Z, Backer G, Grahani I, Taskinen M-R, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey R, Wood D. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis. 2011;217S:S1–S44. [PubMed]
 622. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Jr, Watson K, Wilson PW. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013. doi:pii: S0735-1097(13)06031-2. [PubMed]
 623. Bookstaver D, Nancy P, Pharm B, Hatzigeorgiou C. Effect of Coenzyme Q10 supplementation on statin-Induced myalgias. *Am J Cardiol*. 2012;110:526–529. doi: 10.1016/j.amjcard.2012.04.026. [PubMed] [Cross Ref]
 624. Wyman M, Leonard M, Morledge T. Coenzyme Q10: a therapy for hypertension and statin-induced myalgia? *Cleve Clin J Med*. 2010;77:435–442. doi: 10.3949/ccjm.77a.09078. [PubMed] [Cross Ref]
 625. Díaz-Zagoya JC, Asenjo, Barrón JC, Cárdenas R, Martínez F, Juárez-Oropeza MA. Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet. *Life Sci*. 1999;65:947–956. doi: 10.1016/S0024-3205(99)00324-0. [PubMed] [Cross Ref]

626. Uličná O, Vančová O, Waczulíková I, Božek P, Sikurová L, Bada V, Kucharská J. Liver mitochondrial respiratory function and coenzyme Q content in rats on a hypercholesterolemic diet treated with atorvastatin. *Physiol Res.* 2012;61:185–193. [PubMed]
627. Kang MS, Yang HM, Kang JY, Ryou SH, Kang JS. Effect of coenzyme Q10 and *Ardisia japonica* Blume on plasma and liver lipids, platelet aggregation, and erythrocyte Na efflux channels in simvastatin-treated guinea pigs. *Nutr Res Pract.* 2012;6:414–420. doi: 10.4162/nrp.2012.6.5.414. [PMC free article] [PubMed] [Cross Ref]
628. Ascaso JF, Fernández-Cruz A, González Santos P, Hernández Mijares A, Mangas Rojas A, Millán J, Felipe Pallardo L, Pedro-Botet J, Pérez-Jiménez F, Pía G, Pintó X, Plaza I, Rubiés-Prat J. HDL Forum Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. *Am J Cardiovasc Drugs.* 2004;4:299–314. doi: 10.2165/00129784-200404050-00003. [PubMed] [Cross Ref]
629. Chapman M, Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. *Eur Heart J.* 2010;31:149–164. doi: 10.1093/eurheartj/ehp399. [PMC free article] [PubMed] [Cross Ref]
630. Mabuchi H, Nohara A, Kobayashi J, Kawashiri M, Katsuda S, Inazu A, Koizumi J. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study. *Atherosclerosis.* 2007;195:182–189. doi: 10.1016/j.atherosclerosis.2007.06.010. [PubMed] [Cross Ref]
631. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. *JAMA.* 2007;298:786–798. doi: 10.1001/jama.298.7.786. [PubMed] [Cross Ref]
632. Langsjoen P, Langsjoen A. The clinical use of HMG-CoA reductase inhibitors and the associated depletion of coenzyme Q10, A review of animal and human publications. *Biofactors.* 2003;18:101–11. doi: 10.1002/biof.5520180212. [PubMed] [Cross Ref]
633. Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. *Mol Biotechnol.* 2007;37:31–37. doi: 10.1007/s12033-007-0052-y. [PubMed] [Cross Ref]
634. Mahmoud M, El-Nagar M, El-Bassossy H. Anti-inflammatory effect of atorvastatin on vascular reactivity and insulin resistance in fructose fed rats. *Arch Pharm Res.* 2012;1:155–162. [PubMed]
635. Schroeder M, Belloto R, Hudson R, McInerney M. Effects of antioxidants coenzyme Q10 and lipoic acid on interleukin-1 beta-mediated inhibition of glucose-stimulated insulin release from cultured mouse pancreatic islets. *Immunopharmacol Immunotoxicol.* 2005;27:109–122. [PubMed]
636. Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. *Clin Interv Aging.* 2013;8:47–59. [PMC free article] [PubMed]
637. Kumar A, Kaur H, Devi P, Mohan V. Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. *Pharmacol Ther.* 2009;124:259–268. doi: 10.1016/j.pharmthera.2009.07.003. [PubMed] [Cross Ref]
638. Kučera O, Lotková H, Staňková P, Podhola M, Roušar T, Mezera V, Cervinková Z. Is rat liver affected by non-alcoholic steatosis more susceptible to the acute toxic effect of thioacetamide? *Int J Exp Pathol.* 2011;92:281–289. doi: 10.1111/j.1365-2613.2011.00765.x. [PMC free article] [PubMed] [Cross Ref]
639. Abbas AM, Sakr HF. Simvastatin and vitamin E effects on cardiac and hepatic oxidative stress in rats fed on high fat diet. *J Physiol Biochem.* 2013;69:737–50. doi: 10.1007/s13105-013-0250-y. [PubMed] [Cross Ref]
640. Ferre P. The biology of Peroxisome Proliferator–Activated Receptors relationship with lipid metabolism and insulin sensitivity. *Diabetes.* 2004;53:43–50. doi: 10.2337/diabetes.53.2007.S43. [PubMed] [Cross Ref]

641. Murrow J, Sher S, Ali S, Uphoff I, Patel R, Porkert M, Le N, Jones D, Quyyumi A. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. *J Clin Lipidol*. 2012;6:42–49. doi: 10.1016/j.jacl.2011.08.006. [PubMed] [Cross Ref]
642. Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. *CMAJ*. 2006;174:1124–1129. doi: 10.1503/cmaj.051313. [PMC free article] [PubMed] [Cross Ref]
643. Boone LR, Brooks PA, Niesen MI, Ness GC. Mechanism of resistance to dietary cholesterol. *J Lipids*. 2011;2011:1012–1042. [PMC free article] [PubMed]
644. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. *Cell*. 2006;124:35–46. doi: 10.1016/j.cell.2005.12.022. [PubMed] [Cross Ref]
645. Yang C, McDonald J, Patel A, Zhang Y, Umetani M, Xu F, Westover E, Covey D, Mangelsdorf J, Cohen J, Hobbs H. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. *J Biol Chem*. 2006;281:27816–27826. doi: 10.1074/jbc.M603781200. [PubMed] [Cross Ref]
646. Schmelzer C, Okun J, Haas D, Higuch K, Sawashita J, Mori M, Döring F. The reduced form of coenzyme Q10 mediates distinct effects on cholesterol metabolism at the transcriptional and metabolite level in SAMP1 mice. *IUBMB Life*. 2010;62:812–818. doi: 10.1002/iub.388. [PubMed] [Cross Ref]
647. Bjorkhem I, Meaney S, Diczfalusy U. Oxysterols in human circulation: which role do they have? *Curr Opin Lipidol*. 2002;13:247–253. doi: 10.1097/00041433-200206000-00003. [PubMed] [Cross Ref]
648. Mari A, DeFronzo RA. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. *Diabetologia*. 2003;46:1211–1219. doi: 10.1007/s00125-003-1169-6. [PubMed] [Cross Ref]
649. Wei Y, Rector R, Thyfault J, Ibdah J. Nonalcoholic fatty liver disease and mitochondrial dysfunction. *World J Gastroenterol*. 2008;14:193–199. doi: 10.3748/wjg.14.193. [PMC free article] [PubMed] [Cross Ref]
650. Marcoff L, Paul D, Thompson M. The role of coenzyme Q10 in statin-associated myopathy. *J Am Coll Cardiol*. 2007;49:2231–2237. doi: 10.1016/j.jacc.2007.02.049. [PubMed] [Cross Ref]
651. Kwak HB, Thalacker-Mercer A, Anderson EJ, Lin CT, Kane DA, Lee NS, Cortright RN, Bamman MM, Neuffer PD. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. *Free Radic Biol Med*. 2012;52:198–207. doi: 10.1016/j.freeradbiomed.2011.10.449. [PMC free article] [PubMed] [Cross Ref]
652. Uykulu M, Meiselman HJ, Baskurt OK. Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties. *Clin Hemorheol Microcirc*. 2007;36:25–33. [PubMed]
653. Deichmann R, Lavie C, Andrews S. Coenzyme Q10 and statin-induced mitochondrial dysfunction. *Ochsner J*. 2010;10:16–21. [PMC free article] [PubMed]
654. Kettawan A, Takahashi T, Kongkachuichai R, Charoenkiatkul S, Kishi T, Okamoto T. Protective effects of Coenzyme Q10 on decreased oxidative stress resistance induced by simvastatin. *J Clin Biochem Nutr*. 2007;40:194–202. [PMC free article] [PubMed]
655. Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ischitobi T, Nabeshima Y, Arihiro K, Chayama K. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as biomarker for the attenuation of NASH. *J Gastroenterol*. 2010;45:750–757. doi: 10.1007/s00535-010-0203-y. [PubMed] [Cross Ref]
656. Kapoor P, Kapoor AK. Coenzyme Q10: A novel molecule. *JIACM*. 2013;14:37–45.
657. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. *Am J Cardiol*. 2007;99:1409–1412. doi: 10.1016/j.amjcard.2006.12.063. [PubMed] [Cross Ref]
658. Folch J, Lee M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids

- from animal tissues. *J Biol Chem.* 1957;226:497–509. [PubMed]
659. Bradford M. A Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 1976;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [PubMed] [Cross Ref]
 660. Estabrook R. In: *Methods in Enzymology. Oxidation and Phosphorylation.* Estabrook RW, Pullman ME, editor. New York: Academic Press Inc; 1967. Mitochondrial respiratory control and the polarographic measurement of the ADP: O ratios; pp. 41–47.
 661. Ribeiro RA, Ziegelmann PK, Duncan BB, et al. Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients. *Int J Cardiol.* 2011 [PubMed]
 662. Mangravite LM, Wilke RA, Zhang J, Krauss RM. Pharmacogenomics of statin response. *Curr Opin Mol Ther.* 2008;10(6):555–561. [PubMed]
 663. Wilke RA, Mareedu RK, Moore JH. The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies. *Curr Pharmacogenomics Person Med.* 2008;6(3):150–159. [PMC free article] [PubMed]
 664. Bulbulia R, Bowman L, Wallendszus K, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. *Lancet.* 2011;378(9808):2013–2020. [PMC free article] [PubMed]
 665. Ahmad H, Cheng-Lai A. Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. *Cardiol Rev.* 2010;18(5):264–267. [PubMed]
 666. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. *Nat Rev Drug Discov.* 2003;2(7):517–526. [PubMed]
 667. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. *Arch Intern Med.* 2003;163(5):553–564. [PubMed]
 668. Kohli P, Cannon CP. Statins and safety: can we finally be reassured? *Lancet.* 2011;378(9808):1980–1981. [PubMed]
 669. Mckenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. *Am J Cardiol.* 2006;97(8A):89C–94C. [PubMed]
 670. Wilke RA, Dolan ME. Genetics and variable drug response. *JAMA.* 2011;306(3):306–307. [PMC free article] [PubMed]
 671. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. *JAMA.* 2003;289(13):1681–1690. [PubMed]
 672. Waters DD. Safety of high-dose atorvastatin therapy. *Am J Cardiol.* 2005;96(5A):69F–75F. [PubMed]
 673. Kennedy SP, Barnas GP, Schmidt MJ, Glisczinski MS, Paniagua AC. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. *J Clin Lipidol.* 2011;5(4):308–315. [PubMed]
 674. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. *Am J Cardiol.* 2006;97(8A):69C–76C. [PubMed]
 675. Piro RM, Di Cunto F. Computational approaches to disease gene prediction: rationale, classification and successes. *FEBS J.* 2012 [PubMed]
 676. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. *Expert Opin Drug Saf.* 2011;10(3):373–387. [PubMed]
 677. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. *Curr Opin Lipidol.* 2007;18(4):401–408. [PubMed]
 678. Psaty BM, Vandenbroucke JP. Opportunities for enhancing the FDA guidance on pharmacovigilance. *JAMA.* 2008;300(8):952–954. [PubMed]
 679. Law M, Rudnicka AR. Statin safety: a systematic review. *Am J Cardiol.* 2006;97(8A):52C–60C.

- [PubMed]
680. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. *Nat Rev Drug Discov.* 2007;6(11):904–916. [PMC free article] [PubMed]
 681. Chan J, Hui RL, Levin E. Differential association between statin exposure and elevated levels of creatine kinase. *Ann Pharmacother.* 2005;39(10):1611–1616. [PubMed]
 682. McClure DL, Valuck RJ, Glanz M, Murphy JR, Hokanson JE. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. *J Clin Epidemiol.* 2007;60(8):812–818. [PubMed]
 683. Molokhia M, Mckeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006. *PLoS ONE.* 2008;3(6):e2522. [PMC free article] [PubMed]
 684. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. *JAMA.* 2004;292(21):2585–2590. [PubMed]
 685. Garcia-Rodriguez LA, Masso-Gonzalez EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. *Pharmacoepidemiol Drug Saf.* 2008;17(10):943–952. [PubMed]
 686. Wilke RA, Reif DM, Moore JH. Combinatorial pharmacogenetics. *Nat Rev Drug Discov.* 2005;4(11):911–918. [PubMed]
 687. Mareedu RK, Modhia FM, Kanin EI, et al. Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity. *Prev Cardiol.* 2009;12(2):88–94. [PMC free article] [PubMed]
 688. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med.* 2004;350(15):1495–1504. [PubMed]
 689. Larosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med.* 2005;352(14):1425–1435. [PubMed]
 690. De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA.* 2004;292(11):1307–1316. [PubMed]
 691. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *JAMA.* 2005;294(19):2437–2445. [PubMed]
 692. Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. *Pharmacoepidemiol Drug Saf.* 2007;16(3):352–358. [PubMed]
 693. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. *Curr Opin Lipidol.* 2010;21(4):324–328. [PubMed]
 694. Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. *N Engl J Med.* 2011;365(4):285–287. [PubMed]
 695. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. *Clin Pharmacol Ther.* 2005;78(4):330–341. [PubMed]
 696. Liao JK. Safety and efficacy of statins in Asians. *Am J Cardiol.* 2007;99(3):410–414. [PMC free article] [PubMed]
 697. Baye TM, Wilke RA. Mapping genes that predict treatment outcome in admixed populations. *Pharmacogenomics J.* 2010;10(6):465–477. [PMC free article] [PubMed]
 698. Albert MA, Glynn RJ, Fonseca FA, et al. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. *Am Heart J.* 2011;162(1):106–114. e102. [PubMed]
 699. Baye TM, Tiwari HK, Allison DB, Go RC. Database mining for selection of SNP markers useful in

- admixture mapping. *BioData Min.* 2009;2(1):1. [PMC free article] [PubMed]
700. Eichler EE, Flint J, Gibson G, et al. Missing heritability and strategies for finding the underlying causes of complex disease. *Nat Rev Genet.* 2010;11(6):446–450. [PMC free article] [PubMed]
 701. Thomson G. Significance levels in genome scans. *Adv Genet.* 2001;42:475–486. [PubMed]
 702. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. *Clin Pharmacol Ther.* 2006;80(6):565–581. [PubMed]
 703. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. *Clin Pharmacokinet.* 2008;47(7):463–474. [PubMed]
 704. Kaspera R, Naraharisetti SB, Tamraz B, et al. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis. *Pharmacogenet Genomics.* 2010;20(10):619–629. [PMC free article] [PubMed]
 705. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. *Br J Clin Pharmacol.* 2003;56(1):120–124. [PMC free article] [PubMed]
 706. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. *J Pharmacol Exp Ther.* 2002;301(3):1042–1051. [PubMed]
 707. Geisel J, Kivisto KT, Griesse EU, Eichelbaum M. The efficacy of simvastatin is not influenced by CYP2D6 polymorphism. *Clin Pharmacol Ther.* 2002;72(5):595–596. [PubMed]
 708. Mulder AB, Van Den Bergh FA, Vermes I. Response to “The efficacy of simvastatin is not influenced by CYP2D6 polymorphism” by Geisel et al. *Clin Pharmacol Ther.* 2003;73(5):475. [PubMed]
 709. Mulder AB, Van Lijf HJ, Bon MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. *Clin Pharmacol Ther.* 2001;70(6):546–551. [PubMed]
 710. Nordin C, Dahl ML, Eriksson M, Sjöberg S. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism? *Lancet.* 1997;350(9070):29–30. [PubMed]
 711. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. *Pharmacogenet Genomics.* 2007;17(9):695–707. [PubMed]
 712. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. *Pharmacogenet Genomics.* 2005;15(6):415–421. [PubMed]
 713. Jemal M, Ouyang Z, Chen BC, Teitz D. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. *Rapid Commun Mass Spectrom.* 1999;13(11):1003–1015. [PubMed]
 714. Riedmaier S, Klein K, Hofmann U, et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. *Clin Pharmacol Ther.* 2010;87(1):65–73. [PubMed]
 715. Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? *Pharmacotherapy.* 2008;28(6):755–768. [PubMed]
 716. Matsushima S, Maeda K, Kondo C, et al. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. *J Pharmacol Exp Ther.* 2005;314(3):1059–1067. [PubMed]
 717. Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. *Gastroenterology.* 2006;130(6):1793–1806. [PubMed]
 718. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. *Pharmacogenet Genomics.* 2006;16(12):873–879. [PubMed]

719. Mwinyi J, John A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. *Clin Pharmacol Ther.* 2004;75(5):415–421. [PubMed]
720. Niemi M. Transporter pharmacogenetics and statin toxicity. *Clin Pharmacol Ther.* 2010;87(1):130–133. [PubMed]
721. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. *Clin Pharmacol Ther.* 2005;78(3):260–277. [PubMed]
722. Fiegenbaum M, Da Silveira FR, Van Der Sand CR, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. *Clin Pharmacol Ther.* 2005;78(5):551–558. [PubMed]
723. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. *Clin Pharmacol Ther.* 2009;86(2):197–203. [PubMed]
724. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. *Pharmacogenomics.* 2009;10(10):1617–1624. [PubMed]
725. Tomlinson B, Hu M, Lee VW, et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. *Clin Pharmacol Ther.* 2010;87(5):558–562. [PubMed]
726. Robey RW, To KK, Polgar O, et al. ABCG2: a perspective. *Adv Drug Deliv Rev.* 2009;61(1):3–13. [PMC free article] [PubMed]
727. Generaux GT, Bonomo FM, Johnson M, Doan KM. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. *Xenobiotica.* 2011;41(8):639–651. [PubMed]
728. Chen YC, Chen YD, Li X, et al. The HMG-CoA reductase gene and lipid and lipoprotein levels: the multi-ethnic study of atherosclerosis. *Lipids.* 2009;44(8):733–743. [PMC free article] [PubMed]
729. Chien KL, Wang KC, Chen YC, et al. Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. *Pharmacogenomics.* 2010;11(3):309–317. [PubMed]
730. Donnelly LA, Doney AS, Dannfald J, et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. *Pharmacogenet Genomics.* 2008;18(12):1021–1026. [PubMed]
731. Krauss RM, Mangravite LM, Smith JD, et al. Variation in the 3-hydroxy-3-methylglutaryl coenzyme A reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. *Circulation.* 2008;117(12):1537–1544. [PubMed]
732. Mangravite LM, Medina MW, Cui J, et al. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. *Arterioscler Thromb Vasc Biol.* 2010;30(7):1485–1492. [PMC free article] [PubMed]
733. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. *Circulation.* 2008;118(4):355–362. [PMC free article] [PubMed]
734. Polisecki E, Muallem H, Maeda N, et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. *Atherosclerosis.* 2008;200(1):109–114. [PMC free article] [PubMed]
735. Baker SK, Tarnopolsky MA. Statin-associated neuromyotoxicity. *Drugs Today (Barc)* 2005;41(4):267–293. [PubMed]
736. Gambelli S, Dotti MT, Malandrini A, et al. Mitochondrial alterations in muscle biopsies of patients on statin therapy. *J Submicrosc Cytol Pathol.* 2004;36(1):85–89. [PubMed]
737. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. *Ann Intern Med.* 2002;137(7):581–585. [PubMed]

738. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. *Muscle Nerve*. 2006;34(2):153–162. [PubMed]
739. Peters BJ, Klungel OH, Visseren FL, De Boer A, Maitland-Van Der Zee AH. Pharmacogenomic insights into treatment and management of statin-induced myopathy. *Genome Med*. 2009;1(12):120. [PMC free article] [PubMed]
740. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. *Lipids Health Dis*. 2007;6:7. [PMC free article] [PubMed]
741. Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. *Cardiol Rev*. 2005;13(2):76–79. [PubMed]
742. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. *Am J Cardiol*. 2007;100(9):1400–1403. [PubMed]
743. Johnson TE, Zhang X, Bleicher KB, et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. *Toxicol Appl Pharmacol*. 2004;200(3):237–250. [PubMed]
744. 84. Matzno S, Yasuda S, Juman S, et al. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. *J Pharm Pharmacol*. 2005;57(11):1475–1484. [PubMed]
745. Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. *J Pharmacol Exp Ther*. 2005;314(3):1032–1041. [PubMed]
746. Sakamoto K, Honda T, Yokoya S, Waguri S, Kimura J. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. *FASEB J*. 2007;21(14):4087–4094. [PubMed]
747. Itagaki M, Takaguri A, Kano S, Kaneta S, Ichihara K, Satoh K. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. *J Pharmacol Sci*. 2009;109(1):94–101. [PubMed]
748. Gianfagna F, Cugino D, Santimone I, Iacoviello L. From candidate gene to genome-wide association studies in cardiovascular disease. *Thromb Res*. 2011 [PubMed]
749. McCarthy MI, Hirschhorn JN. Genome-wide association studies: potential next steps on a genetic journey. *Hum Mol Genet*. 2008;17(R2):R156–165. [PMC free article] [PubMed]
750. Antonarakis SE, Beckmann JS. Mendelian disorders deserve more attention. *Nat Rev Genet*. 2006;7(4):277–282. [PubMed]
751. Doerge RW. Mapping and analysis of quantitative trait loci in experimental populations. *Nat Rev Genet*. 2002;3(1):43–52. [PubMed]
752. Holland JB. Genetic architecture of complex traits in plants. *Curr Opin Plant Biol*. 2007;10(2):156–161. [PubMed]
753. Pereira NL, Weinshilboum RM. The impact of pharmacogenomics on the management of cardiac disease. *Clin Pharmacol Ther*. 2011;90(4):493–495. [PMC free article] [PubMed]
754. Fan JB, Chee MS, Gunderson KL. Highly parallel genomic assays. *Nat Rev Genet*. 2006;7(8):632–644. [PubMed]
755. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. *N Engl J Med*. 2008;359(8):789–799. [PubMed]
756. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. *J Am Coll Cardiol*. 2009;54(17):1609–1616. [PMC free article] [PubMed]
757. Donnelly LA, Doney AS, Tavendale R, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. *Clin Pharmacol Ther*. 2011;89(2):210–216. [PMC free article] [PubMed]

758. Peters B, editor. Methodological approaches to the pharmacogenomics of statins. 2010.
759. Wilke RA, Xu H, Denny JC, et al. The emerging role of electronic medical records in pharmacogenomics. *Clin Pharmacol Ther.* 2011;89(3):379–386. [PMC free article] [PubMed]
760. Roden DM, Johnson JA, Kimmel SE, et al. Cardiovascular pharmacogenomics. *Circ Res.* 2011;109(7):807–820. [PMC free article] [PubMed]
761. Isackson PJ, Ochs-Balcom HM, Ma C, et al. Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: Evidence for additional functions of EYS. *Muscle Nerve.* 2011 [PMC free article] [PubMed]
762. Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. *Pharmacogenet Genomics.* 2011;21(5):280–288. [PMC free article] [PubMed]
763. Emily M, Mailund T, Hein J, Schausser L, Schierup MH. Using biological networks to search for interacting loci in genome-wide association studies. *Eur J Hum Genet.* 2009;17(10):1231–1240. [PMC free article] [PubMed]
764. Kasarskis A, Yang X, Schadt E. Integrative genomics strategies to elucidate the complexity of drug response. *Pharmacogenomics.* 2011;12(12):1695–1715. [PubMed]
765. Neale BM, Sham PC. The future of association studies: gene-based analysis and replication. *Am J Hum Genet.* 2004;75(3):353–362. [PMC free article] [PubMed]
766. Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: A review of statistical methods and recommendations for their application. *Am J Hum Genet.* 2010;86(1):6–22. [PMC free article] [PubMed]
767. Baye TM, Butsch Kovacic M, Biagini Myers JM, et al. Differences in candidate gene association between European ancestry and African American asthmatic children. *PLoS ONE.* 2011;6(2):e16522. [PMC free article] [PubMed]
768. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. *Lancet.* 2010;375(9725):1525–1535. [PMC free article] [PubMed]
769. Bansal V, Libiger O, Torkamani A, Schork NJ. Statistical analysis strategies for association studies involving rare variants. *Nat Rev Genet.* 2010;11(11):773–785. [PMC free article] [PubMed]
770. Lettre G, Palmer CD, Young T, et al. Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARE Project. *PLoS Genet.* 2011;7(2):e1001300. [PMC free article] [PubMed]
771. Kwan T, Benovoy D, Dias C, et al. Genome-wide analysis of transcript isoform variation in humans. *Nat Genet.* 2008;40(2):225–231. [PubMed]
772. Clark TA, Schweitzer AC, Chen TX, et al. Discovery of tissue-specific exons using comprehensive human exon microarrays. *Genome Biol.* 2007;8(4):R64. [PMC free article] [PubMed]
773. Xing Y, Ouyang Z, Kapur K, Scott MP, Wong WH. Assessing the conservation of mammalian gene expression using high-density exon arrays. *Mol Biol Evol.* 2007;24(6):1283–1285. [PubMed]
774. Laaksonen R, Katajamaa M, Paiva H, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. *PLoS ONE.* 2006;1:e97. [PMC free article] [PubMed]
775. Laaksonen R. On the mechanisms of statin-induced myopathy. *Clin Pharmacol Ther.* 2006;79(6):529–531. [PubMed]
776. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. *Clin Pharmacol Ther.* 2011;89(3):464–467. [PMC free article] [PubMed]
777. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. *Am J Cardiol.* 2006;97(8A):44C–51C. [PubMed]
778. Pasternak RC, Smith SC, Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. *J Am Coll Cardiol.* 2002;40(3):567–572. [PubMed]
779. Grundy SM. The issue of statin safety: where do we stand? *Circulation.* 2005;111(23):3016–3019.

- [PubMed]
780. Prisant LM, Downton M, Watkins LO, et al. Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia. *Am J Cardiol.* 1996;78(4):420–424. [PubMed]
 781. Jacobson TA, Chin MM, Curry CL, et al. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. *Arch Intern Med.* 1995;155(17):1900–1906. [PubMed]
 782. Puccetti L, Ciani F, Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. *Atherosclerosis.* 2010;211(1):28–29. [PubMed]
 783. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. *Cardiovasc Drugs Ther.* 2005;19(6):403–414. [PubMed]
 784. Hedenmalm K, Alvan G, Ohagen P, Dahl ML. Muscle toxicity with statins. *Pharmacoepidemiol Drug Saf.* 2010;19(3):223–231. [PubMed]
 785. Sinzinger H, O'grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. *Br J Clin Pharmacol.* 2004;57(4):525–528. [PMC free article] [PubMed]
 786. Rowan C, Brinker AD, Nourjah P, et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. *Pharmacoepidemiol Drug Saf.* 2009;18(4):301–309. [PMC free article] [PubMed]
 787. Ray GM. Antiretroviral and statin drug-drug interactions. *Cardiol Rev.* 2009;17(1):44–47. [PubMed]
 788. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. *Clin Pharmacol Ther.* 2004;75(5):455–463. [PubMed]
 789. Ishikawa C, Ozaki H, Nakajima T, et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. *J Hum Genet.* 2004;49(10):582–585. [PubMed]
 790. Ozaki H, Ishikawa CT, Ishii T, et al. Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. *J Clin Pharm Ther.* 2005;30(2):189–192. [PubMed]
 791. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. *Drug Metab Pharmacokinet.* 2004;19(6):453–455. [PubMed]
 792. Brunham LR, Lansberg PJ, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. *Pharmacogenomics J.* 2011 [PubMed]
 793. Furihata T, Satoh N, Ohishi T, et al. Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy. *Pharmacogenomics J.* 2009;9(3):185–193. [PubMed]
 794. Mudd S. H. et al. Homocysteine and its disulfide derivatives: A suggested consensus terminology. *Arterioscler Thromb Vasc Biol.* 20, 1704–1706 (2002). [PubMed]
 795. Nyfard O. et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med.* 337, 230–236 (1997). [PubMed]
 796. Soinio M. et al. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. *Ann Intern Med.* 140, 94–100 (2004). [PubMed]
 797. Cheng S. W., Ting A. C. & Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. *Ann Vasc Surg.* 11, 217–223 (1997). [PubMed]
 798. Perry I. J. et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. *Lancet.* 346, 1395–1398 (1995). [PubMed]
 799. Towfighi A., Saver J. L., Engelhardt R. & Ovbiagele B. Factors associated with the steep increase in late-midlife stroke occurrence among US men. *J Stroke Cerebrovasc Dis.* 17, 165–168 (2008). [PMC free article] [PubMed]
 800. Selhub J. et al. Association between plasma homocysteine concentrations and extracranial carotid-

- artery stenosis. *N Engl J Med.* 332, 286–291 (1995). [PubMed]
801. McQuillan B. M., Beilby J. P., Nidorf M., Thompson P. L. & Hung J. Hyperhomocysteinemia but not the c677t mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The perth carotid ultrasound disease assessment study (cudas). *Circulation.* 99, 2383–2388 (1999). [PubMed]
802. Kim S. J. et al. Biomarkers of asymptomatic carotid stenosis in patients undergoing coronary artery bypass grafting. *Stroke.* 42, 734–739 (2011). [PubMed]
803. Maron B. A. & Loscalzo J. The treatment of hyperhomocystenemia. *Annu Rev Med.* 60, 39–54 (2009). [PMC free article] [PubMed]
804. Loscalzo J. Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology. *J Clin Invest.* 119, 3203–3205 (2009). [PMC free article] [PubMed]
805. Toole J. F. et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA* 291, 565–575 (2004). [PubMed]
806. Lonn E. et al. Heart outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med.* 354, 1567–1577 (2006). [PubMed]
807. Børnaa K. H. et al. NORVIT Trial Investigators: Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med.* 354, 1578–1588 (2006). [PubMed]
808. Cardoso C. R. et al. Factors associated with carotid intima-media thickness and carotid plaques in type 2 diabetic patients. *J Hypertens.* 30, 940–947 (2012). [PubMed]
809. Simon A. et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. *J Hypertens.* 20, 159–169 (2002). [PubMed]
810. O'Leary D. H. et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. *N Engl J Med* 340, 14–22 (1999). [PubMed]
811. Chambless L. E. et al. Carotid wall thickness is predictive of incident clinical stroke. The Atherosclerosis Risk in Communities (ARIC) study. *Am J Epidemiol* 151, 478–487 (2000). [PubMed]
812. Staub D. et al. Prediction of cardiovascular morbidity and mortality: comparison of the internal carotid artery resistive index with the common carotid artery intima-media thickness. *Stroke.* 37, 800–805 (2006). [PubMed]
813. Kurata M., Okura T., Watanabe S. & Higaki J. Association between carotid hemodynamics and asymptomatic white and gray matter lesions in patients with essential hypertension. *Hypertens Res.* 28, 797–803 (2005). [PubMed]
814. van Dijk S. C. et al. Homocysteine level is associated with aortic stiffness in elderly: cross-sectional results from the B-PROOF study. *J Hypertens.* 31, 952–959 (2013). [PubMed]
815. Lim M. H., Cho Y. I. & Jeong S. K. Homocysteine and pulsatility index of cerebral arteries. *Stroke* 40, 3216–3220 (2009). [PubMed]
816. Jacques P. F. et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. *Am J Clin Nutr.* 69, 482–489 (1999). [PubMed]
817. Ricotta J. J. et al. Up dated society for vascular surgery guidelines for management of extracranial carotid disease. *J Vasc Surg.* 54, e1–e31 (2011). [PubMed]
818. Matsuo S. et al. Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis.* 53, 982–992 (2009). [PubMed]
819. Manabe S., Okura T., Watanabe S. & Higaki J. Association between carotid haemodynamics and inflammation in patients with essential hypertension. *J Hum Hypertens.* 19, 787–791 (2005). [PubMed]
820. Rifkin M. D. et al. Evaluation of renal transplant rejection by duplex Doppler examination: value of the resistive index. *Am J Roentgenol.* 148, 759–762 (1987). [PubMed]

- 821. Okura T. et al. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension. *Clin Exp Hypertens.* 30, 415–422 (2008). [PubMed]
- 822. Hoffman M. Hypothesis: hyperhomocysteinemia is an indicator of oxidative stress. *Med Hypotheses.* 77, 1088–1093 (2011). [PubMed]
- 823. McCully K. S. & Ragsdale B. D. Production of arteriosclerosis by homocysteinemia. *Am J Pathol.* 61, 1–11 (1970). [PMC free article] [PubMed]
- 824. Marti-Carvajal A. J. et al. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev.* 1, CD006612 (2013). [PubMed]
- 825. Spence J. D. & Stampfer M. J. Understanding the complexity of homocysteine lowering with vitamins: The potential role of subgroup analyses. *JAMA.* 306, 2610–2611 (2011). [PubMed]
- 826. Spence J. D. B vitamin therapy for homocysteine: Renal function and vitamin B12 determine cardiovascular outcomes. *Clin Chem Lab Med.* 51, 633–637 (2013). [PubMed]
- 827. Debrececi B. & Debrececi L. Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases? *Cardiovasc Ther.* 30, 227–233 (2012). [PubMed]